

**Цитирания на избраните публикации по конкурса за член кореспондент
(Общо 600 цитирания)**

2005 година

1. **Petrova G.**, Benisheva T. Pharmacoeconomics and the new Bulgarian positive list. Regulatory Affair Journal, 2005; 175-178

2007 година

2. Bogavac-Stanojevic N., **Petrova G.**, Jelic Z, Memon L, Spasic S. Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers. Clinical Biochemistry 2007; 40: 1180-1187

Цитирания:

1. Shahbazy M, Zahraei A, Vafaeimanesh J, Kompany-Zareh M. Rapid and non-invasive diagnosis of coronary artery disease via clinical laboratory parameters and ¹H-NMR spectra of human blood plasma. RSC Advances, 2015; 5(126):104054-104061 doi.org/10.1039/C5RA17262D.
2. Haschke-Becher E, Totzke U, Afazel S, Johansson T, Schwarz M, Ladurner G, Wild C. Clinical decision rules for the use of liquor diagnostics in hospitalized neurology patients reduced costs without affecting clinical outcomes. Int J Technol Assess Health Care. 2009 Apr;25(2):208-13. doi: 10.1017/S0266462309090266.
3. De Berardis D, Aiello G, Serroni N, Russo V, Gambi F, Cavuto M, Salerno R.M , Sepede G, Valchera A, Moschetta F, Ferro F.M. . C-REACTIVE PROTEIN: A LITERATURE REVIEW OF ITS IMPLICATIONS IN PSYCHIATRIC DISORDERS. Nova Science Publishers, Inc., 2009; ISBN 978-1-60692-237-8.
4. Zhang Z. A Systematic Review of Economic Evaluations for Interventions of Cardiovascular Diseases. Master thesis (The University of Texas School of Public Health). ProQuest Dissertations Publishing, 2009; 1462479. (<https://www.proquest.com/openview/4f1c025694ee87b87fa40b58216e562e/1?pq-origsite=gscholar&cbl=18750>)
5. Vafaeimanesh J, Hejazi F, Vahedia M, Tabaraii R, Bagherzadeh M, Khalesi A. Evaluation of Risk Factors for Acute Coronary Syndrome in Patients Referring to the Cardiology Clinic of Shahid Beheshti Hospital in Qom City, 2015, Iran. Qom University of Medical Sciences Journal, 2016; Vol. 10, No. 10, Pe51-Pe60.
6. De Berardis D, Serroni N, Campanella D, Moschetta F.S, Ferro F.M. Efficacia e tollerabilità della terapia a lungo termine con aripiprazolo nel trattamento di un paziente con disturbo bipolare tipo I. Giorn Ital Psicopat 2009;15:99-101.

2008 година

3. Stevanovic PD, **Petrova G.**, Miljkovic B, Scepanovic R, Perunovic R, Stojanovic D, Dobrasinovic J. Low fresh gas flow balanced anesthesia versus target controlled intravenous infusion anesthesia in laparoscopic cholecystectomy: a cost-minimization analysis. Clin Ther. 2008 Sep;30(9):1714-25. doi: 10.1016/j.clinthera.2008.09.009.

Цитирания:

1. Kumar G, Stendall C, Mistry R, Gurusamy K, Walker D. A comparison of total intravenous anaesthesia using propofol with sevoflurane or desflurane in ambulatory surgery: systematic review and meta-analysis. *Anaesthesia*. 2014 Oct;69(10):1138-50. doi: 10.1111/anae.12713.
2. Eikaas H, Raeder J. Total intravenous anaesthesia techniques for ambulatory surgery. *Curr Opin Anaesthesiol*. 2009 Dec;22(6):725-9. doi: 10.1097/ACO.0b013e3283310f6b.
3. Amin A, Liu XH, Abbas Q, Hanif I, Vo XV. Globalization, sustainable development, and variation in cost of power plant technologies: A perspective of developing economies. *Environ Sci Pollut Res Int*. 2021 Mar;28(9):11158-11169. doi: 10.1007/s11356-020-10816-x.
4. Çaparlar CÖ, Özhan MÖ, Süzer MA, Yazicioğlu D, Eşkin MB, Şenkal S, Çaparlar MA, Imren EÖ, Atik B, Çekmen N. Fast-track anesthesia in patients undergoing outpatient laparoscopic cholecystectomy: comparison of sevoflurane with total intravenous anesthesia. *J Clin Anesth*. 2017 Feb;37:25-30. doi: 10.1016/j.jclinane.2016.10.036.
5. Talih G, Yüksek A, Şahin E. Evaluation of emergence agitation after general anaesthesia in rhinoplasty patients: Inhalation anaesthesia versus total intravenous anaesthesia. *Am J Otolaryngol*. 2020 May-Jun;41(3):102387. doi: 10.1016/j.amjoto.2020.102387.
6. Malhotra R, Kumar N, Jain A. Cost identification analysis of general anesthesia. *J Anaesthesiol Clin Pharmacol*. 2020 Apr-Jun;36(2):219-226. doi: 10.4103/joacp.JOACP_77_19.
7. Vaughan J, Nagendran M, Cooper J, Davidson BR, Gurusamy KS. Anaesthetic regimens for day-procedure laparoscopic cholecystectomy. *Cochrane Database Syst Rev*. 2014 Jan 24;2014(1):CD009784. doi: 10.1002/14651858.CD009784.
8. Prathep S, Mahattanaporn S, Wasinwong W. Target Controlled Infusion versus Sevoflurane/Desflurane Anesthesia for Laparoscopic Cholecystectomy: Comparison Postoperative Nausea/Vomiting and Extubation Time. *J Med Assoc Thai*. 2015 Dec;98(12):1187-92.
9. Alnemri A, Sussman S, Estephan L, Hamilton C, Stewart M, Zhan T, Thaler A, Ananth A, Boon M, Huntley C, Hunt P. Cost of Total Intravenous Anesthesia Versus Inhalation Anesthesia in Obstructive Sleep Apnea Surgery. *Laryngoscope*. 2022 Jul;132(7):1487-1494. doi: 10.1002/lary.30094.

10. Doger C, Kahveci K, Ornek D, But A, Aksoy M, Gokcinar D, Katar D. Effects of Low-Flow Sevoflurane Anesthesia on Pulmonary Functions in Patients Undergoing Laparoscopic Abdominal Surgery. *Biomed Res Int.* 2016;2016:3068467. doi: 10.1155/2016/3068467.
11. Лихванцев В., Борисов К., Габитов М., Гребенчиков О., Кичин В., Козлова Е., Левиков Д., Мурачев А., Тимошин С., Селиванов Д., Скрипкин Ю., Сунгуров В., Федоров С., Шайбакова В. Ингаляционная индукция и поддержание анестезии (монография). Под редакцией профессора В.В. Лихванцева. 2013; ISBN: 978-5-9986-0107-1.
12. Singh Y, Singh AP, Jain G, Yadav G, Singh DK. Comparative evaluation of cost effectiveness and recovery profile between propofol and sevoflurane in laparoscopic cholecystectomy. *Anesth Essays Res.* 2015 May-Aug;9(2):155-60. doi: 10.4103/0259-1162.156290.
13. Lai HC, Hung NK, Lin BF, Chen JL, Huang YH, Wu ZF. Lower Incidence of Prolonged Extubation in Propofol-Based Total Intravenous Anesthesia Compared with Desflurane Anesthesia in Laparoscopic Cholecystectomy. A Retrospective Study. *Journal of Medical Sciences*, 2019; 39(3):p 121-126 | DOI:10.4103/jmedsci.jmedsci_157_18.
14. Sneyd JR, Holmes KA. Inhalational or total intravenous anaesthesia: is total intravenous anaesthesia useful and are there economic benefits? *Curr Opin Anaesthesiol.* 2011 Apr;24(2):182-7. doi: 10.1097/ACO.0b013e328343f3ac.
15. Chan SM, Horng HC, Huang ST, Ma HI, Wong CS, Cherng CH, Wu CT. Drug Cost Analysis of Three Anesthetic Regimens in Prolonged Lumbar Spinal Surgery. *J Med Sci.* 2009; 29(2):075-080. <http://jms.ndmctsggh.edu.tw/2902075.pdf>
16. Warhadpande S, Martin D, Bhalla T, Rehman S, Rose M, Guinipero T, Tobias JD. Use of ultrasound to facilitate difficult lumbar puncture in the pediatric oncology population. *Int J Clin Exp Med.* 2013;6(2):149-52.
17. Guevara-Farias JC, Rincón-Valenzuela DA, Gómez-Ardila C. Comparison of direct costs associated with the use of balanced general anesthesia and total intravenous anesthesia (TIVA) techniques. *Columbian journal of anaesthesiology*, 2022; Vol. 50 No. 2: e1021 <https://doi.10.5554/22562087.e1021>.
18. Ryksen E, Diedericks BJS. Calculation of comparative utilisation and cost: a South African perspective on intravenous vs. inhalational anaesthesia for procedures of differing duration. *Southern African Journal of Anaesthesia and Analgesia*, 2012; Volume 18, 2012 - Issue 6; Pages 310-317 doi: 10.1080/22201173.2012.10872871.

19. Umberham B, Hedin R, Detweiler B, Kollmorgen L, Hicks C, Vassar M. Heterogeneity of studies in anesthesiology systematic reviews: a meta-epidemiological review and proposal for evidence mapping. *Br J Anaesth*. 2017 Nov 1;119(5):874-884. doi: 10.1093/bja/aex251.
20. Hu J, He Z. Cost of general anesthesia during radical gastrectomy using different specifications of propofol: cost-minimization analyses. *Int J Clin Exp Med*. 2015 Nov 15;8(11):21266-78.
21. Carlos RFJ, Ortiz IR. Dextmedetomidine versus midazolam for continuous sedation in the Intensive Care Unit: A cost analysis in Mexico. *Medicina Crítica*, 2013; 27 (4); Page: 200-207.
22. Shelgaonkar VC, Choudhary A. Low flow anaesthesia: economic, eco friendly and effective. *Indian Journal of Clinical Anaesthesia*, 2017;4(3): 382-387; DOI: 10.18231/2394-4994.2017.0077.
23. Majstorović BM, Milaković BD, Kastratović DA, Milićić BR, Vucićević VR. [Reductions in anesthesia direct costs is not the right way for racionalization of anesthesia costs]. *Med Pregl*. 2012 Sep-Oct;65(9-10):421-7. Serbian. doi: 10.2298/mpns1210421m.
24. Aribawa IGNM, Senapathi TGA, Widnyana IMG, Hartawan IGAU, Pradana AP, Ryalino C. Comparison between Target-Controlled Infusion Propofol and Target-Controlled Inhalational Anesthesia Sevoflurane in Mastectomy Surgery in Indonesia. *Bali Journal of Anesthesiology*, 2021; 5(2):p 61-65, DOI:10.4103/BJOA.BJOA_178_20.
25. Li J. Anesthesia for Nasal and Antral Surgery. Chapter of “Anesthesia for Oral and Maxillofacial Surgery”, 2023; pp 257–271; https://link.springer.com/chapter/10.1007/978-981-19-7287-4_18
26. Erbatur ME, Dedeoglu A, Andic O, Saruhan R, Gokce R, Uzundere O, Gokcek E, Kacar CK. Comparison of Sevoflurane Inhalation Anesthesia and Total Intravenous Anesthesia with Propofol in Terms of Postoperative Sore Throat and Nausea/Vomiting in Septorhinoplasty Cases. *JARSS*. 2023;31(3):188-196; doi: 10.54875/jarss.2023.26879.
27. Choudhary A, Shelgaonkar VC. A Prospective Study to Analyse Safety of Low Flow Anesthesia for Laparoscopic Procedures. *Int J Cur Res Rev*, 2017;; Vol 9, Issue 6, p- 34-39 .
28. Casas-Arroyave FD. Total intravenous anesthesia vs inhalational anesthesia in patients undergoing surgery under general anesthesia. Cost-minimization study. *Colombian Journal of Anesthesiology*, 2022;50(3):e202, doi: 10.5554/22562087.e1023.

29. Kursal G. Evaluation of effects of tiva and inhalation anesthesia in gynecological laparoscopy on hemodynamic response, intraocular pressure and recovery. Master thesis, 2016; https://acikbilim.yok.gov.tr/bitstream/handle/20.500.12812/432090/yokAcikBilim_10138440.pdf?sequence=-1&isAllowed=y
30. BIYIKa I, ALBAYRAKb M, KESKİNe F, Nur MUTd A. The effect of uterine manipulator use in laparoscopic tubal ligation on operation duration and anesthesia drug quantity. Journal of Clinical Obstetrics and Gynecology, 2020;30(1):8-13; Doi: 10.5336/jcog.2020-73653.
31. Maratha V, Kumar S, Dhamija A, Manchanda J. ASSESSMENT OF COST-EFFECTIVENESS AND RECOVERY PROFILE BETWEEN PROPOFOL AND SEVOFLURANE IN PATIENTS UNDERGOING LAPAROSCOPIC CHOLECYSTECTOMY: A COMPARATIVE STUDY. Journal of Advanced Medical and Dental Sciences Research, 2016; 4(5):51-55.; DOI: 10.21276/jamdsr.2016.4.5.14.
32. Majstorović B, Milaković B, Marković S, Kastratović D. Anesthesia Today With the Economic and Clinical Aspects. Hospital Pharmacology - International Multidisciplinary Journal, 2016; vol. 3, (2), 402-408 DOI: 10.5937/hpimj1602402M.
33. Rodríguez FF. Termodinámica de la mezcla estática: aplicaciones médicas y medio ambientales. Universidade da Coruña. Departamento de Medicina- Teses de doutoramento, 2017, <https://ruc.udc.es/dspace/handle/2183/19443>
34. Helmi AH, Esa K, Khairulamir Z, Azarinah I, Nurlia Y, Nadia MN. A Comparison of Soda Lime (Intersurgical) with Amsorb® plus: The Cost Implications. Journal of Surgical Academia, 2016; 6(2): 12-17; DOI: 10.17576/JSA.2016.0602.03.
35. Kaddoum R, Yaacoub CI, McKelvey GM, Wang H. Effects of Circuit Leak Development Over Time and Response During Low-Flow Volume and Pressure-Controlled Ventilation. Middle East Journal of Anaesthesiology, 2016; 23(6):631-637.
36. Yüce HH, Küçük A, Altay N, Alp Karahan M, Büyükfırat E, Yücel Y, Terzi A, Aksoy N. Tiroid ve/veya Paratiroid Cerrahisinde Minimal Akımlı Anestezi ile Düşük Akımlı Anestezinin Oksidatif Stres Üzerine Olan Etkilerinin ve Maliyetlerinin Karşılaştırılması. Journal of Harran university medical faculty, 2016; Volume: 13 Issue: 1, 48 – 53.
37. Doger C, Kahveci K, Ornek D, But A, Aksoy M, Gokcinar D, Katar D. Effects of Low-Flow Sevoflurane Anesthesia on Pulmonary Functions in Patients

Undergoing Laparoscopic Abdominal Surgery. Biomed Res Int. 2016;2016:3068467. doi: 10.1155/2016/3068467.

38. Majstorović B, Milaković B. Analysis of Cost-Utility and Effectiveness in Health Care System – Economic analysis of anesthesiological work. Zdravstvena zaštita, 2010; vol. 39, br. 5, str. 23-33. DOI: 10.5937/ZZ1005023M.

39. ЛИХВАНЦЕВ ВВ, БАСОВ ВЕ, БОЛЬШЕДВОРОВ РВ, СУНГУРОВ ВА;. ИНГАЛЯЦИОННАЯ АНЕСТЕЗИЯ ВЗГЛЯД НА ПРОБЛЕМУ. АНЕСТЕЗИОЛОГИЯ И РЕАНИМАТОЛОГИЯ, 2010; 3, 57-59, Учредители: Издательство "Медицина", ISSN: 0201-7563eISSN: 2410-4698.

4. Fabrice Clerfeuille, Yannick Poubanne, Milena Vakrilova, **Guenka Petrova**, Evaluation of consumer satisfaction using the tetra-class model. Research in Social and Administrative Pharmacy 2008; 4: 258–271

Цитирования:

1. Bélas J, Gabčová L. The relationship among customer satisfaction, loyalty and financial performance of commercial banks. E+M Ekonomie a Management. 2016; vol. 19, issue 1, p. 132-147; DOI:10.15240/tul/001/2016-1-010.
2. Guhl D, Blankart KE, Stargardt T. Service quality and perceived customer value in community pharmacies. Health Serv Manage Res. 2019 Feb;32(1):36-48. doi: 10.1177/0951484818761730.
3. Huang YM, Pu YH, Chen TS, Chiu PS. Development and evaluation of the mobile library service system success model: A case study of Taiwan. The Electronic Library, 2015; Volume33; Issue number6; 1174-1192. DOI: 10.1108/EL-06-2014-0094.
4. Pu YH, Chiu PS, Chen TS, Huang YM. The design and implementation of a Mobile Library APP system. Library Hi Tech, 2015; Volume 33, Number 1, pp. 15-31(17);DOI: 10.1108/LHT-10-2014-0100.
5. Khmour MR, Hallak HO. Societal perspectives on community pharmacy services in West Bank - Palestine. Pharm Pract (Granada). 2012 Jan;10(1):17-24. doi: 10.4321/s1886-36552012000100004.
6. Bena I. Evaluating customer satisfaction in banking services; Management & Marketing, 2010; vol. 5, issue 2; p 143-150.
7. McCarthy L, Milne E, Waite N, Cooke M, Cook K, Chang F, Sproule BA. Sex and gender-based analysis in pharmacy practice research: A scoping review. Res Social Adm Pharm. 2017 Nov;13(6):1045-1054. doi: 10.1016/j.sapharm.2016.11.007.

8. Thuy VTN, Tuu HH, Llosa S, Thao HDP. An application of Tetraclass model for evaluating ecotourism service quality in Vietnam. *Tourism and Hospitality Research*, 2020; 20(3), 300-316. DOI: 10.1177/1467358419867741.
9. Pribadi P, Riska, Kristina SA, Syahlani SP, Satibi. Antecedents and consequence of patients' satisfaction with pharmaceutical service in hospitals: A multidimensional approach. *Pharmacia*, 2023; 70(2): 317–322 DOI 10.3897/pharmacia.70.e101532.
10. Jayaprakash G, Rajan ML, Shivam P. Consumer views of community pharmacy services in Bangalore city, India. *Pharm Pract (Granada)*. 2009 Jul; 7(3):157-62. doi: 10.4321/s1886-36552009000300005.
11. Lostakova H, Horakova V. Procedia; Usefulness of Tools to Enhance Retention and Loyalty in Purchasing OTC Drugs from the Perspective of Clients of B&M Pharmacies. *Social and Behavioral Sciences*, 2014; Volume 150, Pages 576-589; DOI: 10.1016/j.sbspro.2014.09.077.
12. Hamilton JR, Tee S. Expectations-to-value: connecting customers with business offerings. *International Journal of Internet Marketing and Advertising*, 2015; Vol. 9, No. 2, pp 121-140 doi: 10.1504/IJIMA.2015.070716.
13. Hu CP, Yan WW, Hu Y. User satisfaction evaluation of microblogging services in China: using the tetra-class model. *Behaviour & Information Technology*, 2015; Volume 34, Issue 1; Pages 17-32; doi: 10.1080/0144929X.2014.942753.
14. Hamilton J, Tee S. The value-expectations relationship: Connecting customer-perceived value with the expectations of pharmacy-offered services. *Information & Management*, 2010; Vol. 47 .
15. Mircheva N, Pelev S. Building customer loyalty in Swedish pharmacy retail, A comparison of the employee and customer views on loyalty construction in the sector. Lund university, School of economics and management. Master thesis; 2021, <https://lup.lub.lu.se/luur/download?func=downloadFile&recordId=9051119&fileId=9051125>.
16. Yan W, Hu Y, Hu C. Using SEM and TCM to Improve Services to Libraries: A Comparative Study on Chinese Academic Libraries. *The Journal of Academic Librarianship*, 2015; Volume 41, Issue 5, Pages 558-566; doi: 10.1016/j.acalib.2015.07.006.

17. KANOVSKY M, MINARIKOV D, MALOVECKA I, MINARIK P, FOLTAN V. CUSTOMER SATISFACTION WITH PHARMACEUTICAL CARE: ROBUST VALIDATION OF AN INSTRUMENT, ITS FACTOR STRUCTURE, AND PSYCHOMETRIC PROPERTIES. *Acta Poloniae Pharmaceutica ñ Drug Research*, 2017; Vol. 74 No. 6 pp. 1937ñ1944,ISSN 0001-6837 Polish Pharmaceutical Society.
18. Cherecheş MS, Popa CO. Factors Influencing the Choice of a Pharmacy in Romania: Comparation between Studies Performed in 2012 and 2020. *Acta Marisiensis - Seria Medica*,2020; VOLUME 66 (2020): ISSUE 4; pp- 155 – 159; DOI: 10.2478/amma-2020-0029.
19. Nkrumah NEK, Ernest O, Serwah AL, Anaba OA. Examining Complaint Handling Processes among Ghanaian Rural Banks and its Influence on Customer Satisfaction. *International Journal of Economics, Business and Management Studies*, Online Science Publishing,2019; vol. 6(2), pages 285-297.
20. TYLINSKA B, RYNG S, BAROWSKI TG, GSIOROWSKI K. HYPOXIA- SELECTIVE CYTOTOXICITY OF OLIVACINE ANALOGUES. SYNTHESIS AND BIOLOGICAL SCREENING. *Acta Poloniae Pharmaceutica ñ Drug Research*, 2017; Vol. 74 No. 6 pp. 1753- 1759, ISSN 0001-6837 Polish Pharmaceutical Society.
21. Barefield CK. Elements of Service Quality that Increase Sustainability in a Small Independently Owned Pharmacy of an Urban Community . Doctoral Study Project (DSP). Trident University International ProQuest Dissertations Publishing; 2022, <https://www.proquest.com/openview/aadeee03b63c13482d5dc745974d6551/1?pq-origsite=gscholar&cbl=18750&diss=y>
22. Kumar S, Jat RK. PERSPECTIVES OF CUSTOMERS ON THE COMMUNITY PHARMACY SERVICES AVAILABLE IN BANGALORE, INDIA;. *International Journal of Advance and Applied Research* 2023; Vol.10 No.3;nn-897-906, DOI - 10.5281/zenodo.8019781.
23. Palmquist, DS. The role, productivity, and patient satisfaction of surgical nurse practitioners compared to medical surgeons in VHA outpatient surgery clinics. TUI University ProQuest Dissertations. 2010; <https://www.proquest.com/openview/8812e0c9be50473eb28995a8b6e4a9ae/1?pq-origsite=gscholar&cbl=18750>.
24. Khmour MR, Hallak HO. Societal perspectives on community pharmacy services in West Bank - Palestine. *Pharm Pract (Granada)*. 2012 Jan;10(1):17-24. doi: 10.4321/s1886-36552012000100004.
25. AMANKWAH O. A MODEL FOR THE RELATIONSHIP BETWEEN USER SATISFACTION OF HEALTHCARE FACILITIES MANAGEMENT AND CORE

HEALTHCARE BUSINESS. Doctoral Study Project; Faculty of Built Environment and Surveying Universiti Teknologi Malaysia, 2019; <https://core.ac.uk/download/pdf/334606923.pdf>

26. Bernardino da Silva AM. AVALIAÇÃO DA SATISFAÇÃO E FIDELIZAÇÃO DE CLIENTES DA UNIDADE DE SAÚDE ORAL DOS SERVIÇOS DE ASSISTÊNCIA MÉDICO SOCIAL (SAMS). Dissertação de Mestrado em Gestão de Serviços de Saúde, 2017; https://repositorio.iscte-iul.pt/bitstream/10071/14394/1/Ana%20Margarida%20Silva_Tese%20de%20Mestrado_vers%C3%A3oFINAL1.pdf
27. Sholihat NK, Montarat Thavorncharoensap. PATIENT SATISFACTION TOWARDS COMMUNITY PHARMACY: A SYSTEMATIC REVIEW. Mahidol University Research Expo 2014; https://www.researchgate.net/profile/Nia-Sholihat/publication/316470969_MS-34_PATIENT_SATISFACTION_TOWARDS_COMMUNITY_PHARMACY_A_SYSTEMATIC_REVIEW/links/5900070545851565029f4d24/MS-34-PATIENT-SATISFACTION-TOWARDS-COMMUNITY-PHARMACY-A-SYSTEMATIC-REVIEW.pdf
28. Dan M, VASILACHE S, DIMA MA. Customer satisfaction assessment using neural networks modelling. Annals of DAAAM & Proceedings, annual 2009; pp. 1579.

2009

5. **Petrova G.**, A. Stoimenova, M. Manova. COST- EFFECTIVENESS OF PEGINTRON ALFA.2B) IN HCV INFECTION: A BULGARIAN SCENARIO. Archives of Balkan Medical Union 2009; 44 (3) : 215-219
6. Anna D. Ivanova, **Guenka I. Petrova**. HYPERTENSION AND COMMON COMPLICATIONS – ANALYSIS OF THE AMBULATORY TREATMENT COST. Cent Eur J Public Health 2009; 17 (4): 223–230

Цитирания:

1. Baroroh F, Fathonah SS. DIRECT MEDICAL COST OF HYPERTENSION OUTPATIENT IN HOSPITAL X YOGYAKARTA. Jurnal Farmasi Sains dan Praktis, 2017; Vol. III, No. 2, p 6-13 doi: 10.31603/pharmacy.v3i2.1724.
2. Israfil I, Making MA. Blood Glucose Level, Blood Pressure, and Medication Behavior are related to Cardiovascular Complication in Hypertension Patient at Sikumana Public Health Center. Unnes Journal of Public Health, 2020; Vol 9 No 1, p: 50-55 doi: 10.15294/ujph.v9i1.28051.
3. Bueno RF. Evaluation simultaneous nitrification and denitrification in sewage treatment plant full scale. 2016, Doctoral Study Project. <https://doi.org/10.11606/T.3.2017.tde-13042017-093748>

4. Bueno DR. Health care costs and association with physical activity level and nutritional status among hypertensive and diabetic elderly: analysis of SABE Study Health, Wellbeing and Aging, 2010; Doctoral Study Project; <https://doi.org/10.11606/T.6.2016.tde-15032016-143749>
5. Simeonova JI, Tisheva- Gospodinova ST, Todorova YM, Hristova PA, Yanakieva AN, Hristov MI. MEASUREMENT AND COMPARISON OF COSTS OF HYPERTENSIVE PATIENTS AGED 40-89 YEARS TREATED WITH LISINAPRIL AND PERINDOPRIL. J Biomed Clin Res, 2017; Volume 10 Number 2, 2017; DOI:10.1515/jbcr-2017-0018.
7. **Petrova G**, Clerfeuille F, Vakrilova M, Mitkov C, Poubanne Y. The applicability of the tetraclass model to the management of the patient satisfaction in the pharmacies. Pharmacy Practice (Internet) 2009 Jan-Mar;7(1):19-28.

Цитирания:

1. Mafi M, Pratt S, Trupp A. Determining ecotourism satisfaction attributes – a case study of an ecolodge in Fiji. Journal of Ecotourism, 2020; Volume 19, Issue 4; Pages 304-326; doi: 10.1080/14724049.2019.1698585.
2. Martin SL, Baker RP, Piper BJ. Evaluation of urban-rural differences in pharmacy practice needs in Maine with the MaPPNA. Pharm Pract (Granada). 2015 Oct-Dec;13(4):669. doi: 10.18549/PharmPract.2015.04.669.
3. Mináriková D, Malovecká I, Lehocká L, Snopková M, Foltán V. The Assessment of Patient Satisfaction and Attendance of Community Pharmacies in Slovakia. Eur. Pharm. J. LVIII, 2016; (2): 23-29, ISSN 1338-6786 DOI: 10.1515/afpuc-2016-0002.
4. Bonnal L, Moinier X. Elements Of Pharmacy Service And Satisfaction: Patient Versus Consumer?. Journal of Applied Business Research (JABR), 2014; 30(2), 479–488. doi: 10.19030/jabr.v30i2.8419.
5. Billion J, Lejealle C. Understanding the success of a deaf-funder's restaurant between food and empathy's appeal: The case of 1001 signes. Journal of Information Technology Teaching Cases 2023; Vol. 0(0) 1–7 DOI: 10.1177/20438869231208219.
6. Moinier X, Bonnal L. Satisfaction and loyalty of the Pharmacy customers: a public health issue. Gestion et management public, 2019/2 Volume 7 / n° 4 | pages 51- 68; DOI: 10.3917/gmp.074.0051.
7. Windal PM. Eléments de satisfaction : Une propriété inédite du modèle tétraclasse de Llosa. Doctoral Study Project; 2011, DOI : 10.7193/DM.063.09.22.

8. Craveiro, BDCNB. Estratégias de marketing e merchandising aplicadas à Farmácia de oficina: estudo de um caso prático. Doctoral Study Project, 2010; <https://bdigital.ufp.pt/handle/10284/1954>
9. Picoito, CSTPA. Avaliação da experiência dos turistas com as farmácias do Algarve. Master Thesis, 2020; <https://sapientia.ualg.pt/handle/10400.1/15155>
10. Fernandes, MRM. Estudo sobre a satisfação dos utentes com os serviços de farmácia comunitária. Master Thesis, 2012; <https://ubibliorum.ubi.pt/handle/10400.6/1080>

2010

8. Manova M., Stoimenova A., Clerfeuille F., **Petrova G.** Impact of the generic competition on market share and prices of cardiovascular medicines on the Bulgarian pharmaceutical market. Journal of Public Health, 2010; 19 (1): 91-100.

Цитирания:

1. Tenni B, Moir HVJ, Townsend B, Kilic B, Farrell AM, Keegel T, Gleeson D. What is the impact of intellectual property rules on access to medicines? A systematic review. Globalization and Health, 2022; 18(1):40 doi: 10.1186/s12992-022-00826-4 .
2. Zeng W. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China. BMC Health Services Research, 2013; Volume 13, article number 390, doi: 10.1186/1472-6963-13-390.
3. Baek IH, Lee BY, Lee ES, Kwon KI. Pharmacokinetics of angiotensin II receptor blockers in the dog following a single oral administration. Drug Res (Stuttg). 2013 Jul;63(7):357-61. doi: 10.1055/s-0033-1341424.
4. Tenni B, Moir HVJ, Townsend B, Kilic B, Farrell AM, Keegel T, Gleeson D. What is the impact of intellectual property rules on access to medicines? A systematic review. Global Health. 2022 Apr 15;18(1):40. doi: 10.1186/s12992-022-00826-4.
5. Perumal-Pillay VA, Alli SR, Suleman F. The Perceptions of Patient Copayment on the Reported Adherence to Prescription Medication. Global Journal of Health Science, 2018; Vol. 10, No. 11, p.105; doi:10.5539/gjhs.v10n11p105.
6. Liu J, Wang L, Liu C, Zhang X. Impact of price deregulation policy on the affordability of essential medicines for women's health: a panel data analysis. Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):625-631. doi: 10.1080/14737167.2017.1330151.

7. Ковачка Г, Герасимов Н, Камушева М. ДОСТЪПНОСТ И РЕИМБУРСИРАНЕ НА ТЕРАПИЯТА С АНТИХИПЕРЛИПИДЕМИЧНИ ЛЕКАРСТВЕНИ ПРОДУКТИ В БЪЛГАРИЯ. Medical Review - Cardiovascular Diseases, 2020; Vol 51, Issue 2, p10, ISSN 0204-6865.

2011

9. Desancic, S., Stoimenova, A., Savova, A., Manova, M., Petkova, V., **Petrova, G.** Pharmacoeconomics of rare diseases therapy - An example of phenylketonuria (2011) Acta Medica Bulgarica, 38 (1), pp. 84-89.

Цитирания:

1. Schuller Y, Hollak CEM, Gispén-de Wied CC, Stoyanova-Beninska V, Biegstraaten M. Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases. Drugs, 2017; 77(13), 1461-1472. Doi: 10.1007/s40265-017-0788-z.
10. Manova, M., Peikova, L., Peikov, P., **Petrova G.** Patent protection policy in the therapeutic group of statins (2011) Biotechnology and Biotechnological Equipment, 25 (4), pp. 2683-2687. DOI: 10.5504/BBEQ.2011.0066
11. Manova, M., Stoimenova, A., Savova, A., Peikov, P., **Petrova, G.** Utilization and price trends in some reimbursed cardiovascular medicines (2011) Biotechnology and Biotechnological Equipment, 25 (2), pp. 2424-2432. DOI: 10.5504/bbeq.2011.0033

Цитирания:

1. Naumovska Z, Nestorovska AK, Grozdanova A, Hristova K, Dimovski A, Suturkova L, Sterjev Z. Evaluation of statin utilization in the Republic of Macedonia during 2013-2016. Clinicoecon Outcomes Res. 2018 Jun 26;10:339-347. doi: 10.2147/CEOR.S157842.
2. Liu J , Wang L , Liu C , Zhang X. Impact of price deregulation policy on the affordability of essential medicines for women's health: a panel data analysis. Expert Review of Pharmacoeconomics & Outcomes Research, 2017;17(6):625-631 doi: 10.1080/14737167.2017.1330151.
3. Ковачка Г, Герасимов Н, Камушева М. ДОСТЪПНОСТ И РЕИМБУРСИРАНЕ НА ТЕРАПИЯТА С АНТИХИПЕРЛИПИДЕМИЧНИ ЛЕКАРСТВЕНИ ПРОДУКТИ В БЪЛГАРИЯ. Medical Review - Cardiovascular Diseases, 2020; Vol 51, Issue 2, p10, ISSN 0204-6865.
12. Stoimenova, A., Manova, M., Savova, A., Angelovska, B., **Petrova, G.** Reimbursed orphan medicines in Bulgaria and the share of biotechnology-derived products (2011) Biotechnology and Biotechnological Equipment, 25 (2), pp. 2418-2423. DOI: 10.5504/bbeq.2011.0043
13. Ivanova, A., **Petrova, G.**, Wrona, W., Valov, V., Stoimenova, A., Czech, M. Modelling the long-term effect of diabetes therapy. An example with liraglutide (2011) Comptes Rendus de L'Academie Bulgare des Sciences, 64 (3), pp. 449-456.

Цитирания:

1. Bagepally BS, Chaikledkaew U, Gurav YK, Anothaisintawee T, Youngkong S, Chaikunapruk N, McEvoy M, Attia J, Thakkestian A. Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. *BMJ Open Diabetes Res Care*. 2020 Jul;8(1):e001020. doi: 10.1136/bmjdr-2019-001020.
 2. Mandrik O, Knies S, Kalo Z, Severens JL. REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE. *Int J Technol Assess Health Care*. 2015;31(6):434-41. doi: 10.1017/S0266462315000677.
 3. Sadek, M. Cost-effectiveness Analysis of Continuous subcutaneous insulin infusion compared with multiple daily injections in adult patients with type 1 and type 2 Diabetes mellitus: a systematic review. Master Thesis, 2021; <https://repositori.upf.edu/handle/10230/52495>
 4. Georgieva S. Health technology assessment of biotechnology medicines with focus on hospital pharmacy. *International Journal of Biotech Trends and Technology (IJBT)*, 2020; Volume 10 Issue 2; p:16-19. DOI:10.14445/22490183/IJBT-V10I2P603.
14. Dimitrova, M., **Petrova G**. Pharmacoeconomic studies of the highly active antiretrovirus therapy of HIV/AIDS *Pharmacia*, 59 (1-4), pp. 72-84.
15. **Petrova, G.**, Ivanova, A., Czech, M., Valov, V., Wrona, W., Niewada, M., Savova, A. Liraglutide vs. exenatide in combination with metformin and/or sulfonylurea therapy in type 2 diabetes mellitus therapy in Bulgaria: A modelling study. *Comptes Rendus de L'Academie Bulgare des Sciences*, 64 (10), pp. 1507-1514.

Цитирания:

1. Bagepally BS, Chaikledkaew U, Gurav YK, Anothaisintawee T, Youngkong S, Chaikunapruk N, McEvoy M, Attia J, Thakkestian A. Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. *BMJ Open Diabetes Res Care*. 2020 Jul;8(1):e001020. doi: 10.1136/bmjdr-2019-001020.
2. Mandrik O, Knies S, Kalo Z, Severens JL. REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE. *Int J Technol Assess Health Care*. 2015;31(6):434-41. doi: 10.1017/S0266462315000677.
3. Dzhambov AM, Dimitrova DD. Evaluation of the social and economic burden of road traffic noise-attributed myocardial infarction in Bulgarian urban population. *Arh Hig Rada Toksikol*. 2015 Mar;66(1):15-21. doi: 10.1515/aiht-2015-66-2562.
4. Georgieva S. Health technology assessment of biotechnology medicines with focus on hospital pharmacy. *International Journal of Biotech Trends*

and Technology (IJBT), 2020; Volume 10 Issue 2; p:16-19. DOI:10.14445/22490183/IJBT-V10I2P603.

5. Mandrik O, Knies S, Kaly Z, Severens JL. Transferability of Economic Evaluations To Central and Eastern European and Former Soviet Countries. Value Health. 2014 Nov;17(7):A443-4. doi: 10.1016/j.jval.2014.08.1172.
16. Dimitrova, M., **Petrova G.**, Cervenjakova, T., Jancheva, N., Stefanova, M., Manova, M., Savova, A., Stoimenova, A. Budget impact model of new antiretroviral biotechnology medicines for treatment of HIV/AIDS patients in Bulgaria (2011) Biotechnology and Biotechnological Equipment, 25 (3), pp. 2547-2554. DOI: 10.5504/bbeq.2011.0053
17. Lakic, D., **Petrova G.**, Bogavac-Stanojević, N., Jelić-Ivanović, Z. Impact of discounting in pharmacoeconomic modeling. A case study (2011) Biotechnology and Biotechnological Equipment, 25 (3), pp. 2555-2558. DOI: 10.5504/bbeq.2011.0065

Цитирания:

1. Kučan M, Lulić I, Pelčić JM, Mozetič V, Vitezić D. Cost effectiveness of antihypertensive drugs and treatment guidelines. Eur J Clin Pharmacol. 2021 Nov;77(11):1665-1672. doi: 10.1007/s00228-021-03163-4.
2. Shivaani MU, Varghese A. REVIEW ON PHARMACOECONOMIC MODELLING METHODS IN INDIAN HEALTHCARE. World Journal of Pharmaceutical Research, 2021; Volume 10, Issue 4, 458-473. DOI: 10.20959/wjpr20214-20072.

2012

18. Jasmina, T., Genchev, G., Savova, A., Dantchev, N., **Petrova, G.** Cost-effectiveness and activities of daily living in patients with complex regional pain syndrome type I (2012) International Journal of Pharmaceutical Sciences Review and Research, 17 (1), pp. 16-21.

Цитирания:

1. Smart KM, Wand BM, O'Connell NE. Physiotherapy for pain and disability in adults with complex regional pain syndrome (CRPS) types I and II. Cochrane Database Syst Rev, 2022; 17;5(5):CD010853. doi: 10.1002/14651858.CD010853.pub3.
2. Mandrik O, Knies S, Kalo Z, Severens JL. REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE. Int J Technol Assess Health Care. 2015;31(6):434-41. doi: 10.1017/S0266462315000677.
3. O. Mandrik O, Knies S, Kaly Z, Severens JL. Transferability of Economic Evaluations To Central and Eastern European and Former Soviet Countries. Value Health. 2014 Nov;17(7):A443-4. doi: 10.1016/j.jval.2014.08.1172.
19. Lakić, D., **Petrova G.**, Bogavac-Stanojević, N., Jelić-Ivanović, Z., Kos, M. The cost-effectiveness of hypertension pharmacotherapy in Serbia: A Markov model (2012) Biotechnology and Biotechnological Equipment, 26 (3), pp. 3066-3072.

Цитирания:

1. Aminde LN, Takah NF, Zapata-Diomed B, Veerman JL. Primary and secondary prevention interventions for cardiovascular disease in low-income and middle-income countries: a systematic review of economic evaluations. *Cost Eff Resour Alloc.* 2018 Jun 14;16:22. doi: 10.1186/s12962-018-0108-9.
2. Mandrik O, Knies S, Kalo Z, Severens JL. REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE. *Int J Technol Assess Health Care.* 2015;31(6):434-41. doi: 10.1017/S0266462315000677.
3. Ho TY, Fishman PA, Zabinsky ZA. Using a game-theoretic approach to design optimal health insurance for chronic disease. *IIE Transactions on Healthcare Systems Engineering*, 2019; Volume 9, Issue 1; Pages 26-40; doi: 10.1080/24725579.2019.1567626.
4. ESTHER M, SOPYAN I, ABDASSAH M. REVIEW ANALISIS EFEKTIVITAS BIAYA TERAPI HIPERTENSI DARI BERBAGAI NEGARA. *Farmaka Suplemen*, 2016; Volume 14 Nomor 2; p 182-194. DOI : 10.24198/jf.v14i2.10802.
5. Ho TY. Optimizing Healthcare Policies through Healthcare Delivery and Insurance Design. Master thesis. 2019; <https://digital.lib.washington.edu/researchworks/handle/1773/44328>
6. Gous AGS. Cost-based optimisation of chronic heart disease interventions. Master thesis. 2016 ; <https://repository.nwu.ac.za/handle/10394/19215>
7. Mandrik O, Knies S, Kaly Z, Severens JL. Transferability of Economic Evaluations To Central and Eastern European and Former Soviet Countries. *Value Health.* 2014 Nov;17(7):A443-4. doi: 10.1016/j.jval.2014.08.1172.
20. Valov V, Palmer J, Czech M, Savova A, **Petrova G**. Cost-effectiveness of biphasic insulin aspart 30 vs. human premix insulin in type 2 diabetes from the payer's perspective in Bulgaria. *Biotechnol Biotechnol Equip.* 2012;26(2):2937-44.

Цитирания:

1. Hua X, Lung TW, Palmer A, Si L, Herman WH, Clarke P. How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review. *Pharmacoeconomics.* 2017 Mar;35(3):319-329. doi: 10.1007/s40273-016-0466-0.
2. Mandrik O, Knies S, Kalo Z, Severens JL. REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE. *Int J Technol Assess Health Care.* 2015;31(6):434-41. doi: 10.1017/S0266462315000677.
3. Farshchi A, Aghili R, Oskuee M, Rashed M, Noshad S, Kebriaeezadeh A, Kia M, Esteghamati A. Biphasic insulin Aspart 30 vs. NPH plus regular human

insulin in type 2 diabetes patients; a cost-effectiveness study. BMC Endocr Disord. 2016 Jun 9;16(1):35. doi: 10.1186/s12902-016-0116-8.

4. Mandrik O, Knies S, Kaly Z, Severens JL. Transferability of Economic Evaluations To Central and Eastern European and Former Soviet Countries. Value Health. 2014 Nov;17(7):A443-4. doi: 10.1016/j.jval.2014.08.1172.

21. Savova A, **Petrova G**, Gotseva A, Kurcatova A, Koguharova M. Economic analysis 20 years after the introduction of universal HBV immunisation in Bulgaria. Biotechnol Biotechnol Equip. 2012;26(1): 2811-6.

Цитирания:

1. La Torre G, Mannocci A, Saulle R, Colamesta V, Meggiolaro A, Mipatrini D, Sinopoli A. Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013). Hum Vaccin Immunother. 2016 Sep;12(9):2299-311. doi: 10.1080/21645515.2016.1166328.

22. Peikova L, Manova M, Pencheva I, **Petrova G**. Chirality as a patent protection policy - an example with citalopram. Biotechnol Biotechnol Equip. 2012;26(3):3058-61.

Цитирания:

1. Balkanski S. HPLC determination of Escitalopram in tablet dosage forms. Pharmacia, 2022; 69(1): 21–24 DOI 10.3897/pharmacia.69.e77878.

2013

23. Nataša Bogavac-Stanojević, Violeta Dopsaj, Zorana Jelić-Ivanović, Dragana Lakić, Dragan Vasić, **Guenka Petrova**. Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis. Biochemia Medica 2013;23(1):96–106 <http://dx.doi.org/10.11613/BM.2013.012>

Цитирания:

1. Lippi G, Tripodi A, Simundic AM, Favaloro EJ. International survey on D-dimer test reporting: a call for standardization. Semin Thromb Hemost. 2015 Apr;41(3):287-93. doi: 10.1055/s-0035-1549092.
2. Werner K, Risko N, Burkholder T, Munge K, Wallis L, Reynolds T. Cost-effectiveness of emergency care interventions in low and middle-income countries: a systematic review. Bull World Health Organ. 2020 May 1;98(5):341-352. doi: 10.2471/BLT.19.241158.
3. Rinaldi I, Hamonangan R, Azizi MS, Cahyanur R, Wirawan F, Fatya AI, Budiananti A, Winston K. Diagnostic Value of Neutrophil Lymphocyte Ratio and D-Dimer as Biological Markers of Deep Vein Thrombosis in Patients Presenting with Unilateral Limb Edema. J Blood Med. 2021 May 20;12:313-325. doi: 10.2147/JBM.S291226.
4. Zhang Y, Begum HA, Grewal H, Etxeandia-Ikobaltzeta I, Morgano GP, Khatib R, Nieuwlaar R, Ding C, Wiercioch W, Mustafa RA, Lim W, Schünemann HJ. Cost-effectiveness of diagnostic strategies for venous thromboembolism: a systematic review. Blood Adv. 2022 Jan 25;6(2):544-567. doi: 10.1182/bloodadvances.2020003576.

5. Mandrik O, Knies S, Kalo Z, Severens JL. REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE. *Int J Technol Assess Health Care*. 2015;31(6):434-41. doi: 10.1017/S0266462315000677.
6. Fuentes EMC. Orientación diagnóstica de la trombosis venosa profunda en la atención primaria. Estudio de coste-efectividad. Doctoral Study Project, 2016; <https://ddd.uab.cat/record/176036>
7. Pinto CG, Duarte R, Mendes JZ. Relevance of In Vitro Diagnosis in the Clinical and Economic Optimization of Diabetes Management. *Revista Portuguesa de Diabetes*. 2020; 15 (4): 106-113.
8. Werner K. Assessing the cost-effectiveness of facility-based emergency care in low resource settings. Doctoral Thesis, 2021; <https://open.uct.ac.za/items/57ee2595-cd8a-41ce-8e30-5c349ff4cff8>
9. Rosa-Jiménez F, Rosa-Jiménez A, Lozano-Rodríguez A, Martín-Moreno P, Hinojosa-Martínez MD, Montijano-Cabrera ÁM. Is time to search the Wells Score 4.0? *Rev Clin Esp (Barc)*. 2015 Jun-Jul;215(5):258-64. English, Spanish. doi: 10.1016/j.rce.2014.10.016.
10. Mandrik O, Knies S, Kaló Z, Severens JL. Transferability of Economic Evaluations To Central and Eastern European and Former Soviet Countries. *Value Health*. 2014 Nov;17(7):A443-4. doi: 10.1016/j.jval.2014.08.1172.
24. **Петрова Г.**, Етични аспекти на фармацевтичните научни изследвания. Сборник статии от 9-та нац. Конференция с межд. Участие на тема етика 2013; 178-181 - добавено
25. Марчева М., Тошева Л., **Г. Петрова**, Модели на ценообразуване и реимбурсация на лекарства в страните от Централна и Източна Европа. Сборник статии от 9-та нац. Конференция с межд. Участие на тема етика 2013; 193-199
26. М. Димитрова, М. Донева и **Г. Петрова**. Изчисляване на бюджетното въздействие на лечението на имунодефицитни състояния със заместителна терапия с човешки нормален имуноглобулин за подкожно приложение. Детски и инфекциозни болести, 2013; 1: 38-43
27. Kamusheva, M., Stoimenova, A., Doneva, M., Zlatareva, A., **Petrova, G.** A cross-country comparison of reimbursed orphan medicines in Bulgaria, Greece and Romania (2013) *Biotechnology and Biotechnological Equipment*, 27 (5), pp. 4186-4192, DOI: 10.5504/BBEQ.2013.0066

Цитирания:

1. Gammie T, Lu CY, Babar ZU. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. *PLoS One*. 2015 Oct 9;10(10):e0140002. doi: 10.1371/journal.pone.0140002.

2. Detiček A, Locatelli I, Kos M. Patient Access to Medicines for Rare Diseases in European Countries. *Value Health*. 2018 May;21(5):553-560. doi: 10.1016/j.jval.2018.01.007.
3. Gombocz M, Vogler S. Public spending on orphan medicines: a review of the literature. *J Pharm Policy Pract*. 2020 Oct 13;13:66. doi: 10.1186/s40545-020-00260-0.
4. Diadiun T, Baranova I, Musozoda S, Semeniv D, Zaporozhska S. Commodity analysis of medical products used in adult incontinence. *Pharmacia*, 2021; 68(4): 805–809 DOI 10.3897/pharmacia.68.e73181.
5. Nedelcheva Y. COMPETITION AND COMPETITIVENESS IN PHARMACEUTICAL INDUSTRY. *Journal: Икономика и управление* Issue Year: 16/2019, Issue No: 2, Page Range: 66-77.
6. Gubyal VK, Goudanavar PS, Elangoli S, Saj A. Orphan drugs overview and regulatory review procedure. *International Journal Of Drug Regulatory Affairs*, 2023; Volume 11, Issue 2, page : 86- 93; Article DOI : 10.22270/ijdra.v11i2.609.
28. Petkova, E., Petkova, V., Konstantinova, M., **Petrova G**. Economic evaluation of continuous subcutaneous insulin infusion for children with diabetes - a pilot study: CSII application for children - economic evaluation (2013) *BMC Pediatrics*, 13 (1), art. no. 155, DOI: 10.1186/1471-2431-13-155

Цитирания:

1. Moucheraud C, Lenz C, Latkovic M, Wirtz VJ. The costs of diabetes treatment in low and middle-income countries: a systematic review. *BMJ Glob Health*, 2019;4:e001258. doi:10.1136/bmjgh-2018-001258.
2. Pihoker C, Forsander G, Fantahun B, Virmani A, Corathers S, Benitez-Aguirre P, Fu J, Maahs DM. ISPAD Clinical Practice Consensus Guidelines 2018: The delivery of ambulatory diabetes care to children and adolescents with diabetes. *Pediatr Diabetes*. 2018 Oct;19 Suppl 27:84-104. doi: 10.1111/pedi.12757.
3. Gururaj Setty S, Crasto W, Jarvis J, Khunti K, Davies MJ. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgrad Med J*. 2016 Mar;92(1085):152-64. doi: 10.1136/postgradmedj-2015-133716.
4. Blair J, McKay A, Ridyard C, Thornborough K, Bedson E, Peak M, Didi M, Annan F, Gregory JW, Hughes D, Gamble C. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT. *Health Technology Assessment (Winchester, England)*, 2018; 22(42):1-112, doi: 10.3310/hta22420.

5. Schiel R, Burgard D, Perenthaler T, Stein G, Kramer G, Steveling A. Use and Effectiveness of Continuous Subcutaneous Insulin Infusion (CSII) and Multiple Daily Insulin Injection Therapy (MIT) in Children, Adolescents and Young Adults with Type 1 Diabetes Mellitus. *Exp Clin Endocrinol Diabetes*. 2016 Feb;124(2):99-104. doi: 10.1055/s-0042-101155.
6. Анциферов МБ, Кантемирова МА, Демидов НА, Калашникова МФ. Фармакоэпидемиологический анализ инсулинотерапии сахарного диабета 1 типа (по данным Московского сегмента Федерального регистра сахарного диабета) ; *Сахарный диабет*, 2023; Том 26; 5; doi: 10.14341/DM12962.
7. Omar D, Alsanae H, Al Khawari M, Abdulrasoul M, Rahme Z, Al Refaei F, Behbehani K, Shaltout A. An Audit of Clinical Practice in a Single Centre in Kuwait: Management of Children on Continuous Subcutaneous Insulin Infusion and Cardiovascular Risk Factors Screening. *Open Cardiovasc Med J*. 2017 Feb 28;11:19-27. doi: 10.2174/1874192401711010019.
8. Петкова – Кунчева М.Д. Хронични вирусни хепатити при пациенти с краен стадий на хронична бъбречна недостатъчност и бъбречна трансплантация; Докторска дисертация,, 2023; <https://www.proquest.com/openview/dfaee2b9a45f1267cb895a2cb4de4d71/1?pq-origsite=gscholar&cbl=2026366&diss=y>
9. Tolkushin AV. OVERVIEW OF PHARMACOECONOMIC STUDIES OF INSULIN PUMP THERAPY IN DIABETES MELLITUS. *Pharmateca*,2016; Issue: 5 (318),Pages: 89-95.
10. Sadek M. Cost-effectiveness Analysis of Continuous subcutaneous insulin infusion compared with multiple daily injections in adult patients with type 1 and type 2 Diabetes mellitus: a systematic review. Master Thesis, 2021; <https://repositori.upf.edu/handle/10230/52495>
11. Bazdarska J. Innovations Improving Treatment Success in Children and Adolescents With Diabetes. Doctoral Study Project, 2020;<https://www.proquest.com/openview/fbe84f7ba46759913372ae50ca3e8f0d/1?pq-origsite=gscholar&cbl=2026366&diss=y>
12. Pihokera C, Forsanderb G, Fantahunc B, Virmanid A, Luoe X, Hallmanb M, Wolfsdorff J, Maahsg D. ISPAD Clinical Practice Consensus Guidelines 2014 Compendium, The Delivery of ambulatory diabetes care to children and adolescents with diabetes, 2014; doi: 10.1111/pedi.12181.
29. Doneva, M., Valov, V., Borisova, A.-M., Tankova, T., Savova, A., Manova, M., Czech, M., **Petrova G**. Comparative analysis of the cost of insulin treated patients in Bulgaria (2013) *Biotechnology and Biotechnological Equipment*, 27 (2), pp. 3748-3752. DOI:

Цитирания:

1. Erku DA, Ayele AA, Mekuria AB, Belachew SA, Hailemeskel B, Tegegn HG. The impact of pharmacist-led medication therapy management on medication adherence in patients with type 2 diabetes mellitus: a randomized controlled study. *Pharm Pract (Granada)*. 2017 Jul-Sep;15(3):1026. doi: 10.18549/PharmPract.2017.03.1026.
 2. Ratnasari PMD, Andayani TM, Endarti D. Analisis Outcome Klinis Berdasarkan Kualitas Hidup dan Biaya Medik Langsung Pasien Diabetes Melitus Tipe 2. *J Sains Farm Klin*,2020; 7(1):15–22 DOI: 10.25077/jsfk.7.1.15-22.2020.
 3. Levterova B, Levterov G, Dragova E, Grudeva T, Kostourkov Y. Bulgarian version of the Audit of Diabetes-Dependent Quality of Life (ADDQoL-19). *Biotechnology & Biotechnological Equipment*, 2017; Volume 31,Issue 3, Pages 581-587; doi: 10.1080/13102818.2017.1297689.
30. Kamusheva MS, N Gerasimov, Guenka I Petrova. Intestinal gel Levodopa+ Carbidopa in Parkinson's patients with frequent and prolonged akinesia-an economic evaluation. *Int J Pharm Sci Rev Res*, 2013; 22 (1): 244-246

Цитирания

1. Rodríguez-Blázquez, C., Forjaz, M. J., Lizán, L., Paz, S., & Martínez-Martín, P. (2015). Estimating the direct and indirect costs associated with Parkinson's disease. *Expert Review of Pharmacoeconomics & Outcomes Research*, 15(6), 889–911. <https://doi.org/10.1586/14737167.2015.1103184>
2. Afentou Nafsika, Johan Jarl, Ulf-G Gerdtham, Sanjib Saha. Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review. *Movement disorders*, 2019; 6 (4): 282-290 <https://doi.org/10.1002/mdc3.12755>
3. Wang L, Li J and Chen J (2018) Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis. 2018; *Front. Neurol.* 9:620. doi: 10.3389/fneur.2018.00620
4. Smilowska K., van Wamelen D., Pietrzykowski T., Calvano A., Rodriguez-Blazquez C., Martinez-Martin P., Odin P., Chaudhuri K. Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review. *Journal of Parkinson's Disease*, 2021; 11 (2): 475-489, 202110.3233/JPD-202348
5. Mandrik O, Knies S, Kalo Z, Severens JL. REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE. *International Journal of Technology Assessment in Health Care*. 2015;31(6):434-441. doi:10.1017/S0266462315000677
6. HERMIDA GUTIÉRREZ, Nelson H.; SANABRIA BECERRA, Lina M.; DÍAZ ROJAS, Jorge A. The assessment of pharmacoeconomic studies quality of Levodopa's use for the management of Parkinson's diseases, 2010-2015. *Revista Colombiana de Ciencias Químico-Farmacéuticas*, 2017, 46.2: 256-

277.

7. Carmen Rodríguez-Blázquez, Maria João Forjaz, Luis Lizán, Silvia Paz & Pablo Martínez-Martín (2015): Estimating the direct and indirect costs associated with Parkinson's disease, Expert Review of Pharmacoeconomics & Outcomes Research, DOI:10.1586/14737167.2015.1103184
8. Mandrik, O., et al. "Transferability of Economic Evaluations To Central and Eastern European and Former Soviet Countries." Value in Health 17.7 (2014): A443-A444.
31. Dimitrova, M., **Petrova, G.**, Manova, M., Savova, A., Yancheva, N., Cervenjakova, T., Mitov, K., Stefanova, M. Economic impact of the highly active antiretroviral pharmacotherapy on cost and HIV/AIDS control in Bulgaria (2013) Biotechnology and Biotechnological Equipment, 27 (1), pp. 3599-3604. DOI: 10.5504/bbeq.2012.0076
32. **G. Petrova**, N Mateev, D Barumov, L Peikova et al .Modeling the Customer Satisfaction Influence on the Long Term Sales: Example with Leading OTC Analgesics INN on National Market. Modern Economy, 2013; 4: 567-595
33. Odalović M, D Lakić, I Tadić, L Tasić, **G Petrova** How much do we pay for caesarean section: A pilot study in Serbia, Acta chirurgica iugoslavica, 2013; 60 (1): 47-51
34. Svetla Georgieva, **Guenka Petrova**, Maria Dimitrova, Lily Peikova, Emil Paskalev, Jean Filipov, Borelli Zlatkov. Prospective Study of the Changes in pharmacotherapy. Cost of Adult Kidney Transplant Patients in Bulgaria. Modern Economy. Vol.4 No.12(2013), Article ID:40809,5 pages DOI:10.4236/me.2013.412089

Цитирания:

1. Nikoogoftar M, Shahini Z. The effects of resilience training on self-efficacy, empowerment, and social adjustment of renal transplant patients. Journal of Nursing & Midwifery Sciences, 2021; Vol 8, Issue 3, p137. DOI 10.4103/jnms.jnms_173_20.
2. Samarehfecri A, Zakeri MA, Mirza HK, Aziz AR, Dehghan M. Effect of Foot Reflexology on Laboratory Tests after Kidney Transplantation Surgery: A Secondary Analysis of a Parallel Randomized Controlled Trial Study. OBM Transplantation 2023; Volume 7, Issue 2, p:92-108. doi:10.21926/obm.transplant.2302186.
3. Maslakpak MH, Abkhiz S, Khalkhali H. THE EFFECT OF THE IMPLEMENTATION OF FAMILY-CENTERED EMPOWERMENT MODEL ON THE QUALITY OF LIFE FOR KIDNEY TRANSPLANT PATIENTS. Nursing and Midwifery Journal 2018; 15(10): 724-732.
4. Vahed AS, Mansouri A, Noushirvani S. Investigation of the Effect of Jig-Saw Training on Care Burden of the Main Caregiver of Patients Undergoing Renal Transplantation Surgery. International Research Journal of Pharmacy and Medical Sciences (IRJPMS), 2018; Volume 1, Issue 5, pp. 63-66.

5. Turri JAO. Análise do custo dos pacientes em lista de espera para o transplante hepático. Master's Dissertation, 2017. Doi: 10.11606/D.5.2017.tde-04102021-151927.
35. Savova A, Kamusheva M, Georgieva S, Stoimenova A, **Petrova G**. Budget impact analysis of chronic myeloid leukemia treatment in bulgaria. Biotechnol Biotechnol Equip. 2013;27(1):3595-8.

Цитирания:

1. Abdallah K, Huys I, Claes K, Simoens S. Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review. Front Pharmacol. 2021 Apr 21;12:630949. doi: 10.3389/fphar.2021.630949.
2. PACZKOWSKA A, KUS K, NOWICKA M, KOPCIUCH D, ZAPRUTKO T, KOMARNICKI M, NOWAKOWSKA E. ANALYSIS OF CHRONIC MYELOID LEUKEMIA PHARMACOTHERAPY COSTS IN POLAND. Acta Poloniae Pharmaceutica- Drug Research, 209; Vol. 76 No. 1 pp. 175=-183, DOI: 10.32383/appdr/93666 Polish Pharmaceutical Society.
3. Tongtong L, Fang Z. Research on Economic Evaluation of Rare Diseases. Research on Economic Evaluation of Rare Diseases/Asian Journal of Social Pharmacy, 2017, 12(2), p. 74- 80.

2014

36. Inotai, A., **Petrova, G**., Vitezic, D., Kaló, Z. Benefits of investment into modern medicines in Central-Eastern European countries (2014) Expert Review of Pharmacoeconomics and Outcomes Research, 14 (1), pp. 71-79. DOI: 10.1586/14737167.2014.868314

Цитирания:

1. Zurynski Y, Herkes-Deane J, Holt J, McPherson E, Lamprell G, Dammery G, Meulenbroeks I, Halim N, Braithwaite J. How can the healthcare system deliver sustainable performance? A scoping review. BMJ Open. 2022 May 24;12(5):e059207. doi: 10.1136/bmjopen-2021-059207.
2. Jimenez T. Expectations and Outcomes of Choosing Reiki for Rheumatoid Arthritis. Doctoral Study Project, 2021; Walden University ProQuest Dissertations Publishing.
<https://www.proquest.com/openview/fd8702813d98dd28f8f540892a3e8a44/1?pq-origsite=gscholar&cbl=18750&diss=y>
3. De Bond RV. Strategies to Sustainability and Increase Cash Flow of Small Hospitals in the Midst of the Healthcare Policy Changes. Doctoral Study Project, 2020. Colorado Technical University ProQuest Dissertations Publishing.
<https://www.proquest.com/openview/d7194b8538eaca7944d80efb05c047a2/1?pq-origsite=gscholar&cbl=18750&diss=y>

4. Pšenková M, Psota M, Suchanský M, Ondrušová M. Vplyv zavedenia prahovej hodnoty nákladov na QALY na zaraďovanie onkologických liekov. *Onkológia (Bratisl.)*, 2017;12(2): 96–99.
37. Danko, D., **Petrova, G.** Health technology assessment in the Balkans: Opportunities for a balanced drug assessment system (2014) *Biotechnology and Biotechnological Equipment*, 28 (6), pp. 1181-1189. DOI: 10.1080/13102818.2014.978636

Цитирования:

1. Ponsiglione AM, Ricciardi C, Improta G, Orabona GD, Sorrentino A, Amato F, Romano M. A Six Sigma DMAIC methodology as a support tool for Health Technology Assessment of two antibiotics. *Math Biosci Eng.* 2021 Apr 19;18(4):3469-3490. doi: 10.3934/mbe.2021174.
2. Beletsi A, Koutrafouris V, Karampli E, Pavi E. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union. *Value Health Reg Issues.* 2018 Sep;16:81-91. doi: 10.1016/j.vhri.2018.08.002.
3. Wortley S, Street J, Lipworth W, Howard K. What factors determine the choice of public engagement undertaken by health technology assessment decision-making organizations? *J Health Organ Manag.* 2016 Sep 19;30(6):872-90. doi: 10.1108/JHOM-08-2015-0119.
4. García-Mochón L, Espín Balbino J, Olry de Labry Lima A, Caro Martinez A, Martin Ruiz E, Pérez Velasco R. HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey. *Health Policy.* 2019 Feb;123(2):182-190. doi: 10.1016/j.healthpol.2017.03.010.
5. Maljichi D, Limani B, Spier TE, Angjelkoska V, Stojković Zlatanović S, Maljichi D, Alloqi Tahirbegolli I, Tahirbegolli B, Kulanić A, Agolli Nasufi I, Kovač-Orlandić M. (Dis)trust in doctors and public and private healthcare institutions in the Western Balkans. *Health Expect.* 2022 Aug;25(4):2015-2024. doi: 10.1111/hex.13562.
6. Huic M, Tandara Hacek R, Svajger I. HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL, EASTERN, AND SOUTH EUROPEAN COUNTRIES: CROATIA. *Int J Technol Assess Health Care.* 2017 Jan;33(3):376-383. doi: 10.1017/S026646231700054X.
7. Guzvic V, Catic T, Kostic M. HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL-EASTERN AND SOUTH EUROPE COUNTRIES: BOSNIA AND HERZEGOVINA. *Int J Technol Assess Health Care.* 2017 Jan;33(3):390-395. doi: 10.1017/S0266462317000058.
8. ÇINAROĞLU S. NEED FOR BALANCED PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT FOR LOW- AND MIDDLE-INCOME COUNTRIES. *Hacettepe Sağlık İdaresi Dergisi*, 2021; 24(4): 885-902.

9. Medarević A. Performance evaluation of general public hospitals in territories of the Former Yugoslavia: An ecological study using the Pabon Lasso model. *Health Planning and Management*, 2022; Volume37, Issue4, Pages 2106-2121. doi: 10.1002/hpm.3453.
10. Tomić Z, Tomas A, Benšova Z, Tomić L, Horvat O, Varga I, Paut Kusturica M, Sabo A. Challenges of Providing Access to Cutting-Edge Cancer Medicines in the Countries of Eastern Europe. *Front Public Health*. 2018 Jul 24;6:193. doi: 10.3389/fpubh.2018.00193.
11. Qehaja B. The Framework of a Real-time Patient Monitoring System Doctoral Study Project, University of Budapest, 2020; https://phd.lib.uni-corvinus.hu/1089/1/Besnik_Qehaja_den.pdf
12. Kaštelan U, Konatar M. The Impact of Health Capital on Economic Growth in the Balkan Countries. *ENTERprise REsearch INNOVation*, 2022; Vol. 8 No. 1, pp 99-107. DOI: 10.54820/entrenova-2022-0010.
13. Jurisevic M. Book Review: Health Economics and Policy Challenges in Global Emerging Markets. *Front Public Health*. 2017; 5: 244. doi: 10.3389/fpubh.2017.00244.
14. Çınaroğlu S. Equity and Healthcare Reform in Developing Economies. 2020. https://doi.org/10.4324/9781003095989_eBook ISBN9781003095989
15. Pokvic LG, Spahic L, Badnjevic A. Implementation of Industry 4.0 in Transformation of Medical Device Maintenance Systems. Chapter of : *Handbook of Research on Integrating Industry 4.0 in Business and Manufacturing*, 2020; DOI: 10.4018/978-1-7998-2725-2.ch023.
16. World Health Organization, regional office for Europe, Copenhagen; 2020. (WHO/EURO:2020-1303-41053-55733). CURRENT STATUS OF HEALTH INTERVENTION AND TECHNOLOGY ASSESSMENT IN THE BALKAN REGION. Report: <https://iris.who.int/bitstream/handle/10665/336228/WHO-EURO-2020-1303-41053-55733-eng.pdf>
17. Христов Г. Критичен анализ и модел за развитие и усъвършенстване на български подход при оценка на здравните технологии. *Medical*, 2016; 20, p. 24-34. https://www.researchgate.net/profile/George-Christoff/publication/280238702_Kriticen_analiz_i_model_za_razvitie_i_usvrsenstvane_na_blgarski_podhod_pri_OZT/links/55aec31608ae98e661a6f145/Kriticen-analiz-i-model-za-razvitie-i-usvrsenstvane-na-blgarski-podhod-pri-OZT.pdf
18. Мавров М. ОЦЕНКАТА НА ЗДРАВНИТЕ ТЕХНОЛОГИИ В ЕВРОПЕЙСКИЯ СЪЮЗ: НЕОБХОДИМИЯТ ИНСТРУМЕНТ ЗА ГАРАНТИРАНЕ НА

19. Christina K. Legal, Financial and Moral implications of CART' introduction in clinical practice. ARISTOTLE UNIVERSITY OF THESSALONIKI , Master Thesis, 2018; <https://ikee.lib.auth.gr/record/303762/files/GRI-2019-24002.pdf>
 20. Dabanovic V. Convergent validation pharmacoeconomic aspects of treatment of benign prostatic. Doctoral Study Project, Универзитет у Крагујевцу, Факултет медицинских наука, 2016; <https://nardus.mpn.gov.rs/handle/123456789/5503>
 21. Gajić-Kvašček M. Non-destructive characterisation of archaeological ceramic artefacts and sourcing the origin using pattern recognition methods. Doctoral Study Project. Универзитет у Београду, Технолошко-металуршки факултет, 2013; <https://doiserbia.nb.rs/phd/fulltext/BG20130318GAJICKVASCEV.pdf>
 38. **Petrova, G.**, Tachkov, K., Georgieva, S., Dimitrova, M. Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: Prophylactic vs. on-demand treatment (2014) Biotechnology and Biotechnological Equipment, 28 (3), pp. 576-582. DOI: 10.1080/13102818.2014.926687
- Цитирания:**
1. Pizarro DB, Pizarro G, Fernando C. Determinación de costos médicos directos del tratamiento de la hemofilia tipo B sin inhibidores en Colombia. Master Thesis, Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019; <https://repository.udca.edu.co/handle/11158/1378>.
39. Mitkova, Z., Manova, M., **Petrova, G.** Impact of the generic competition on reference prices of cardiovascular medicines (2014) Pharmacia, 61 (3), pp. 9-16.
 40. Lakić, D., Petrović, B., **Petrova, G.** Cost-effectiveness analysis of different types of labor for singleton pregnancy: Real life data (2014) Srpski Arhiv za Celokupno Lekarstvo, 142 (11-12), pp. 688-694. DOI: 10.2298/SARH1412688L
- Цитирания:**
1. Wang W. Costs-effectiveness Analysis of Elective Cesarean Section Compared with Vaginal Delivery: a prospective cohort study in a hospital in León, Nicaragua. Mater Thesis, Uppsala University, 2016; <https://www.diva-portal.org/smash/get/diva2:941815/FULLTEXT03.pdf>
41. Valov, V., Doneva, M., Borisova, A.M., Tankova, T., Czech, M., Manova, M., Savova, A., Peikova, L., **Petrova, G.** Regional differences in diabetic patients' pharmacotherapy in Bulgaria (2014) European Review for Medical and Pharmacological Sciences, 18 (10), pp. 1499-1506.

Цитирания:

1. Brodsky V, Beretzky Z, Baji P, Rencz F, Péntek M, Rotar A, Tachkov K, Mayer S, Simon J, Niewada M, Hren R, Gulácsi L. Cost-of-illness studies in nine Central and Eastern European countries. *Eur J Health Econ.* 2019 Jun;20(Suppl 1):155-172. doi: 10.1007/s10198-019-01066-x.
2. Levterova B, Levterov G, Dragova E. Quality of Life in Patients with Type 2 Diabetes Mellitus in Bulgaria: A Cross - Sectional Study. *European Journal of Preventive Medicine* 2016; 4(1): 7-12 doi: 10.11648/j.ejpm.20160401.12.
3. Choi HE, Lee JW, Je NK, Jeong KH. Use of SGLT2 inhibitor/metformin fixed dose combination in Korea. *Korean Journal of Clinical Pharmacy*, 2022; Volume 32, Issue 1, pages:13-19; doi: 10.24304/kjcp.2022.32.1.13.
4. Levterova B, Levterov G, Dragova E, Grudeva T, Kostourkov Y. Bulgarian version of the Audit of Diabetes-Dependent Quality of Life (ADDQoL-19). *Biotechnology & Biotechnological Equipment*, 2017; Volume 31, Issue 3, Pages 581-587; doi: 10.1080/13102818.2017.1297689.
5. Mironova D, Grigorov E, Belcheva V, Handjieva-Darlenska T. Inhibitors of sodium-glucose linked transporter 2 - A new class antidiabetic drugs used for the treatment of diabetes mellitus type 2. *Annual for hospital pharmacy*, 2017, 2016; II; 1; 59-65. DOI:10.14748/.v2i1.1891.
6. Миронова Д. ФАРМАКОЛОГИЧНИ ИЗСЛЕДВАНИЯ ВЪРХУ РОЛЯТА НА ХОРМОНАЛНИТЕ НАРУШЕНИЯ ПРИ ДИСФУНКЦИЯ НА ЩИТОВИДНАТА ЖЛЕЗА. ДИСЕРТАЦИОНЕН ТРУД ЗА ОБРАЗОВАТЕЛНА И НАУЧНА СТЕПЕН „ДОКТОР“. Медицински университет-София, 2022; <https://www.proquest.com/openview/b7c7adb1a75b9e18957e7c946d73319a/1?pq-origsite=gscholar&cbl=2026366&diss=y>
7. Beretzky Z. THE ROLE OF THE COST OF DISEASES AND QUALITY OF LIFE IN THE ALLOCATION OF HEALTHCARE RESOURCES. PH. D. THESIS, CORVINUS UNIVERSITY OF BUDAPEST, 2020; <https://core.ac.uk/download/pdf/328921616.pdf>.
42. Gulácsi, L., Rotar, A.M., Niewada, M., Löblöv, O., Rencz, F., **Petrova, G.**, Boncz, I., Klazinga, N.S. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria (2014) *European Journal of Health Economics*, 15 (SUPPL. 1), pp. S13-S25. DOI: 10.1007/s10198-014-0590-8

Цитирания:

1. Kennedy-Martin M, Slaap B, Herdman M, van Reenen M, Kennedy-Martin T, Greiner W, Busschbach J, Boye KS. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. *Eur J Health Econ.* 2020 Nov;21(8):1245-1257. doi: 10.1007/s10198-020-01195-8.

2. Cameron D, Ubels J, Norström F. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. *Glob Health Action*. 2018;11(1):1447828. doi: 10.1080/16549716.2018.1447828.
3. Baltussen R, Marsh K, Thokala P, Diaby V, Castro H, Cleemput I, Garau M, Iskrov G, Olyaeemanesh A, Mirelman A, Mobinizadeh M, Morton A, Tringali M, van Til J, Valentim J, Wagner M, Youngkong S, Zah V, Toll A, Jansen M, Bijlmakers L, Oortwijn W, Broekhuizen H. Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. *Value Health*. 2019 Nov;22(11):1283-1288. doi: 10.1016/j.jval.2019.06.014.
4. Fontrier AM, Visintin E, Kanavos P. Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries. *Pharmacoecoon Open*. 2022 May;6(3):315-328. doi: 10.1007/s41669-021-00311-5.
5. Kaló Z, Gheorghe A, Huic M, Csanádi M, Kristensen FB. HTA Implementation Roadmap in Central and Eastern European Countries. *Health Econ*. 2016 Feb;25 Suppl 1(Suppl Suppl 1):179-92. doi: 10.1002/hec.3298.
6. Kall M, Fresán U, Guy D, Brown G, Burgui C, Castilla J, Grecu VI, Dumitrescu F, Delpech V, Lazarus JV. Quality of life in people living with HIV in Romania and Spain. *BMC Infect Dis*. 2021 Sep 13;21(Suppl 2):898. doi: 10.1186/s12879-021-06567-w.
7. Oortwijn W, Determann D, Schiffers K, Tan SS, van der Tuin J. Towards Integrated Health Technology Assessment for Improving Decision Making in Selected Countries. *Value Health*. 2017 Sep;20(8):1121-1130. doi: 10.1016/j.jval.2017.03.011.
8. Beletsi A, Koutrafouris V, Karampli E, Pavi E. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union. *Value Health Reg Issues*. 2018 Sep;16:81-91. doi: 10.1016/j.vhri.2018.08.002.
9. Fuchs S, Olberg B, Panteli D, Busse R. HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES IN EUROPE: PROCESSES, PRACTICES, AND METHODS. *Int J Technol Assess Health Care*. 2016;32(4):246-255. doi: 10.1017/S0266462316000349.
10. Olariu E, Caplescu R, Vale L, Niculescu-Aron IG, Oluboyede Y, Paveliu MS. Population norms for the EQ-5D-3L and EQ-5D-5L in Romania. *Health Qual Life Outcomes*. 2023 Jul 29;21(1):80. doi: 10.1186/s12955-023-02144-8.

11. Németh B, Goettsch W, Kristensen FB, Piniashko O, Huić M, Tesař T, Atanasijevic D, Lipska I, Kaló Z. The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries. *Expert Rev Pharmacoecon Outcomes Res.* 2020 Aug;20(4):321-330. doi: 10.1080/14737167.2020.1779061.
12. Löblová O. Three worlds of health technology assessment: explaining patterns of diffusion of HTA agencies in Europe. *Health Economics, Policy and Law*, 2016; vol. 11, issue 3, 253-273. DOI: 10.1017/s1744133115000444.
13. Antoñanzas F, Terkola R, Postma M. The Value of Medicines: A Crucial but Vague Concept. *Pharmacoeconomics.* 2016; 34(12):1227-1239. doi: 10.1007/s40273-016-0434-8.
14. Ghijben P, Gu Y, Lancsar E, Zavarsek S. Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review. *Pharmacoeconomics.* 2018 Mar;36(3):323-340. doi: 10.1007/s40273-017-0586-1.
15. Gałązka-Sobotka M, Kowalska-Bobko I, Lach K, Mela A, Furman M, Lipska I. Recommendations for the Implementation of Hospital Based HTA in Poland: Lessons Learned From International Experience. *Front Pharmacol.* 2021 May 13;11:594644. doi: 10.3389/fphar.2020.594644.
16. Kolossváry E, Björck M, Behrendt CA. A Divide between the Western European and the Central and Eastern European Countries in the Peripheral Vascular Field: A Narrative Review of the Literature. *J Clin Med.* 2021 Aug 12;10(16):3553. doi: 10.3390/jcm10163553.
17. Abraham K, Franken M. A SWOT analysis of the complex interdependencies of the Maltese reimbursement processes. *Health Policy OPEN*, 2023; Volume 4, art. num: 100095 doi: 10.1016/j.hpopen.2023.100095.
18. García-Mochón L, Espín Balbino J, Olry de Labry Lima A, Caro Martinez A, Martin Ruiz E, Pérez Velasco R. HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey. *Health Policy.* 2019 Feb;123(2):182-190. doi: 10.1016/j.healthpol.2017.03.010.
19. Bailey H, Janssen MF, La Foucade A, Boodraj G, Wharton M, Castillo P. EQ-5D self-reported health in Barbados and Jamaica with EQ-5D-5L population norms for the English-speaking Caribbean. *Health Qual Life Outcomes.* 2021 Mar 19;19(1):97. doi: 10.1186/s12955-021-01734-8.
20. Ozieranski P, King LP. Governing drug reimbursement policy in Poland: The role of the state, civil society, and the private sector. *Theor Soc*, 2017; 46:577–610 DOI: 10.1007/s11186-017-9300-8.

21. Péntek M, Kobelt G, Berg J, Capsa D, Dalén J, Bíró Z, Mátyás K, Komoly S. New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary. *Mult Scler*, 2017;23(2_suppl):91-103. doi: 10.1177/1352458517708142.
22. Rais C, Kaló Z, Csanádi M, Negulescu V. Current and future perspectives for the implementation of health technology assessment in Romania. *Health Policy and Technology*, 2020; Volume 9, Issue 1, Pages 45-52 DOI: 10.1016/j.hlpt.2019.11.007.
23. Vončina L, Strbad T, Fürst J, Dimitrova M, Kamusheva M, Vila M, Mardare I, Hristova K, Harsanyi A, Atanasijević D, Banović I, Bobinac A. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe. *Appl Health Econ Health Policy*. 2021 Nov;19(6):915-927. doi: 10.1007/s40258-021-00678-w.
24. Büssgen M, Stargardt T. Does health technology assessment compromise access to pharmaceuticals?. *Eur J Health Econ*. 2023; 24(3): 437–451. doi: 10.1007/s10198-022-01484-4.
25. Németh B, Csanádi M, Kaló Z. OVERVIEW ON THE CURRENT IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN THE HEALTHCARE SYSTEM IN HUNGARY. *Int J Technol Assess Health Care*. 2017 Jan;33(3):333-338. doi: 10.1017/S0266462317000071.
26. Bailey H, Janssen MF, La Foucade A, Castillo P, Boodraj G. Health-Related Quality of Life Population Norms for Belize Using EQ-5D-5L. *Value Health Reg Issues*. 2022 May;29:45-52. doi: 10.1016/j.vhri.2021.09.005.
27. Więckowska B, Raulinajtys-Grzybek M, Byszek K. Using the Dynamic SWOT Analysis to Assess Options for Implementing the HB-HTA Model. *IJERPH*, 2022; vol. 19, issue 12, 1-17. DOI: 10.3390/ijerph1912728.
28. Lipska I, McAuslane N, Leufkens H, Hövels A. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND. *Int J Technol Assess Health Care*. 2017 Jan;33(3):350-357. doi: 10.1017/S0266462317000563.
29. Iskrov G, Stefanov R. Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria. *Balkan Med J.*, 2016 ; 33(1): 27–35. doi: 10.5152/balkanmedj.2015.15185.
30. Kani C, Kourafalos V, Litsa P. CURRENT ENVIRONMENT FOR INTRODUCING HEALTH TECHNOLOGY ASSESSMENT IN GREECE. *Int J Technol Assess Health Care*. 2017 Jan;33(3):396-401. doi: 10.1017/S0266462317000629.
31. Lakner Z, Kiss A, Popp J, Zéman Z, Máté D, Oláh J. From Basic Research to Competitiveness: An Econometric Analysis of the Global Pharmaceutical

- Sector. Sustainability, 2019, vol. 11, issue 11, p.3125. DOI 10.3390/su11113125.
32. Kotvitska AA, Nemchenko AS, Nazarkina VN. The relevance of training specialists in the Health Technology Assessment in the world and Ukraine. *Pharmacia*, 2020; 67(4): 295–301 DOI 10.3897/pharmacia.67.e54777.
 33. Beatrice D, Zsuzsanna S. The impacts of a new type of actor as an intermediary in public–private collaboration in health-care prevention. *The Journal of Business and Industrial Marketing*, 2020; Volume 36, Number 3, pp. 420-435(16). DOI: 10.1108/JBIM-12-2019-0509.
 34. Рудакова АВ, Брико НИ, Лобзин ЮВ, Намазова-Баранова ЛС, Авдеев СН, Коршунов ВА, Костинов МП, Игнатова ГЛ, Блинова ЕВ, Концевая АВ, Шепель РН, Дроздова ЛЮ, Драпкина ОМ. Фармакоэкономическая эффективность вакцинации против пневмококковой инфекции пациентов с сахарным диабетом. *Эпидемиология и вакцинопрофилактика*, 2022; Том 21, (5), 78-88. DOI: 10.31631/2073-3046-2022-21-5-78-88.
 35. Rogalewicz V, Barták M. Controversies around QALYs. *Vnitr Lek* 2017; 63(4):242-248 | DOI: 10.36290/vnl.2017.051.
 36. RUDAKOVA AV, BRIKO NI, LOBZIN YV, NAMAZOVA-BARANOVA LS, AVDEEV N, KOROLEVA IS, KORSHUNOV VA, KOSTINOV MP, KONTSEVAYA AV, SHEPEL RN. DROZDOVA L.Y., DRAPKINA O.M. Cost-effectiveness of vaccination of elderly citizens against pneumococcal infection in the Russian Federation. *The Russian Journal of Preventive Medicine*, 2021; vol. 24, no 12, pp. 41-48 DOI: 10.17116/profmed20212412141.
 37. Vostalová L, Mazelová J, Samek J, Vocelka M. HEALTH TECHNOLOGY ASSESSMENT IN EVALUATION OF PHARMACEUTICALS IN THE CZECH REPUBLIC. *Int J Technol Assess Health Care*, 2017 ;33(3):339-344. doi: 10.1017/S0266462317000204.
 38. Lach K, Dziwisz M, Rémuzat C, Toumi M. Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines. *J Mark Access Health Policy*. 2017 Jul 26;5(1):1355202. doi: 10.1080/20016689.2017.1355202.
 39. Zawada A, Mäkelä M. HTA IN CENTRAL-EASTERN-SOUTHERN EUROPE: FINDING ITS WAY TO HEALTH POLICY. *Int J Technol Assess Health Care*, 2017; 33(3):331-332. doi: 10.1017/S0266462317000988.
 40. Mbau R. A critical examination of the policy process, implementation, and institutionalization of explicit healthcare priority-setting at the macro-level

in Kenya. PhD thesis, London School of Hygiene & Tropical Medicine, 2023; DOI:10.17037/PUBS.04671823 .

41. Рудакова АВ, Вильниц АА, Харит СМ, Лобзин ЮВ. Фармакоэкономические аспекты вакцинации детей первого года жизни против менингококковой инфекции в РФ. Журнал инфектологии, 2021; Том 13 (4), 113-120 DOI: 10.22625/2072-6732-2021-13-4-113-120.
42. Kovács A. Cost of illness in benign prostatic hyperplasia: A review. Society and Economy, 2015; Volume/Issue: Volume 37: Issue 4, Pages: 531–542. DOI: 10.1556/204.2015.37.4.7 .
43. Rogalewicz V, Kubátová I, Donin G, Doležal T, Lamblová K, Bartáková J, Kneppo P. HTA in the Czech Republic: Still Behind. World Congress on Medical Physics and Biomedical Engineering 2018. Conference paper pp 101–105.
44. Vlčková J, Klimková V. The digital transformation of Czech healthcare: trends and COVID-19 impact. Int. J. Electronic Healthcare, 2023; Vol. 13, No. 1, pp:15-32 .
45. Buriskova K, Rogalewicz V, Ostadal P. COST-EFFECTIVENESS OF EXTRACORPOREAL MEMBRANE OXYGENATION IN RESUSCITATION OF PATIENTS WITH REFRACTORY CARDIAC ARREST. E+M Ekonomie a Management, 2019; Vol. 22, Issue 2. pp-161-172 DOI: 10.15240/tul/001/2019-2-011.
46. Ayhan A. Evaluation of the effectiveness of health services in the OECD countries by data envelopment analysis method. Master thesis, 2018; <https://platform.almanhal.com/Details/Thesis/2000193556?ID=4-2000193556>
47. Beretzky Z. THE ROLE OF THE COST OF DISEASES AND QUALITY OF LIFE IN THE ALLOCATION OF HEALTHCARE RESOURCES. PH. D. THESIS, CORVINUS UNIVERSITY OF BUDAPEST, 2020; <https://core.ac.uk/download/pdf/328921616.pdf>.
48. Dean ECB. Impacts of Pharmaceutical Price Controls on Pricing, Sales, and Market-level Quality: Evidence from India. Doctoral Study Project. University of Pennsylvania ProQuest Dissertations. 2018; <https://www.proquest.com/openview/dbb14dddc8909edf6779c33847068eff/1?pq-origsite=gscholar&cbl=18750>
49. Rozmarinová J , Říhová B. Health Technology Assessment of the Medical Devices: A Case Study from the Czech Republic. NISPAcee Journal of Public Administration and Policy, 2021, vol. 14, issue 2, 253-272. DOI: 10.2478/nispa-2021-0022.

50. Farkas K, Kolossváry E. Screening and care of patients with lower extremity arterial disease in Hungary. *LEGE ARTIS MEDICINAE*, 2022; 32 (3). pp. 87-94
DOI: 10.33616/lam.32.007
51. Kovács Á. A gyógyszeresen kezelt jóindulatú prosztatamegnagyobbodásban szenvedő betegek életminősége Magyarországon – Keresztmetszeti felmérés hat urológiai centrumban. *MAGYAR UROLÓGIA*, 2017; XXIX. ÉVFOLYAM, 4. 173–179 DOI: 10.22591/magyuro.2017.4.kovacs.173.
52. ROGALEWICZ V, BARTÁK M. QALYs and cost-effectiveness thresholds: critical reflections. *Central European Conference in Finance and Economics*, 2017. Conference paper; pp:664-677 .
53. Schulman KA. Pharmacoeconomics. The Economics of Pharmaceuticals. Chapter No34 of “Pharmacoepidemiology, Sixth Edition”, 2019; Online ISBN:9781119413431 | DOI:10.1002/9781119413431.
54. Kolev Z. Pharmaceutical Policy in Bulgaria – Effects of Reference Pricing and Market Entry of Generic Drugs. Master Thesis, Medical university Varna, 2019; <https://eprints.mu-varna.bg/handle/nls/539>
55. Moradi M, Kovács A. Current issues of healthcare resource allocation in Iran; *Health Technology Assessment. Köz-gazdaság*, 2019; 14 (1). pp. 204-217. DOI: 10.14267/RETP2019.01.22 .
56. Tamasi B. Betegségteher és mérésének jelentősége pemphigusban. Doctoral Study Project. Budapest, 2018; DOI:10.14753/SE.2019.2241
<https://core.ac.uk/download/pdf/232187866.pdf>
57. Benisheva T, Trendafilova PD, Sidjimova DA, Vodenicharov TV. Comparative Analysis of The Guidelines for Conducting Hta in Poland and Bulgaria. *Value in health*, 2016; VOLUME 19, ISSUE 7, PA506, doi.org/10.1016/j.jval.2016.09.927.
58. Newham R, Corcoran ED, Dear JW, Hems S, McTaggart S, Bennie M. A qualitative study of the relationship between the Scottish Medicines Consortium and their clinical experts. *J Eval Clin Pract*. 2016 Jun;22(3):311-8. doi: 10.1111/jep.12325.
43. Dimitrova M, **Petrova G**, Tachkov K, Bozhkova MK, Kamusheva M, Mitov K. Economic consequences of the vaccination against hepatitis A in the bulgarian healthcare setting. *Biotechnol Biotechnol Equip*. 2014;28(2):366-71.

Цитирания:

1. Baymakova M, Kunchev M, Mihaylova-Garnizova R, Zasheva A, Plochev K, Kundurzhiev T, Tsachev I. Comparative Analysis on Clinical Characteristics

Among Patients with Acute Hepatitis A Virus (HAV) and Patients with Acute Hepatitis E Virus (HEV): A Single-Center Retrospective Study from Bulgaria. Infect Drug Resist. 2023 May 29;16:3349-3366. doi: 10.2147/IDR.S411606.

2. Walsh N, Torres J, Curtis S. Hepatitis A childhood and adolescent vaccination: a systematic review of the effectiveness, immunogenicity, impact, safety and cost effectiveness of pediatric vaccines. Final report to the World Health Organization Strategic Advisory Group of Experts on Immunization Working Group on hepatitis A vaccines. SAGE Hepatitis A vaccines Systematic review report, 9 March 2022 https://www.nitag-resource.org/sites/default/files/2022-12/sage_hepatitisa_wg_systematic_review_09mar22.pdf
3. Kevorkyan A, Raycheva R, Markova E, Presti AL, Angeletti S, Ciccozzi M, Teoharov P. Prevalence of Hepatitis A virus in Bulgaria. J Virol Antivir Res, 2015; 4:2 art. Number 1000139 DOI: 10.4172/2324-8955.1000139.
4. Severi E. Epidemiology, prevention and control of hepatitis A virus infection in the European Union. Master Thesis, m Department of Medical Epidemiology and Biostatistics Karolinska Institutet, Stockholm, Sweden, 2022;
<https://www.proquest.com/openview/d5a374a85a5498229521d7c973e2fecf/1?cbl=2026366&diss=y&pq-origsite=gscholar>
5. Стоицова С. ВИРУСЕН ХЕПАТИТ А: РАЗПРОСТРАНЕНИЕ И МЕРКИ ЗА ПРЕВЕНЦИЯ И КОНТРОЛ В БЪЛГАРИЯ И ПО СВЕТА. Meditsinski Pregled, 2019; Vol 55, Issue 2, p5.
6. Georgieva S. Health technology assessment of biotechnology medicines with focus on hospital pharmacy. International Journal of Biotech Trends and Technology (IJBT), 2020; Volume 10 Issue 2; p:16-19. DOI:10.14445/22490183/IJBT-V10I2P603.
7. Vekov T. Cost-effectiveness analysis of health technologies for second line therapy of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. MEDICAL REVIEW, 2018; vol. LIV, № 3, p 55-59.
44. Benbassat BV, M Doneva, **GI Petrova** -Pharmacotherapy Cost of Controlled Ovarian Hyperstimulation of in Vitro Fertilization-A Real Life Study. Pharmacology & Pharmacy, 2014; 5 (10): 919-23

Цитирания:

1. Aldweik G, Malik S, Almuhammidi A, Alyoubi W, Alsulami A, Al-Oufi H. PHARMACEUTICAL SEARCH ENGINE. 18th International Conference e-Society 2020; p-81-88; ISBN: 978-989-8704-14-6.

2015

45. Petrov, M., Dimitrova, M., **Petrova, G.** Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not on Dialysis in Bulgaria (2015) Value in Health Regional Issues, 7, pp. 94-103. DOI: 10.1016/j.vhri.2015.09.004

Цитирания:

1. Wang F, Lu X, Zhang J, Xiong R, Li H, Wang S. Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials. *Kidney Blood Press Res.* 2018;43(2):536-544. doi: 10.1159/000488700.
46. Dimitrova M, Doneva M, Valov V, Yordanova S, Manova M, Savova A, Mitov K, **Petrova G**, Petkova V, Czech M. Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria. *Biotechnol Biotechnol Equip.* 2015; 29(4):805-13.

Цитирания:

1. Kharyal A, Ranjan S, Jaswal S, Parveen D, Gupta GD, Thareja S, Verma SK. Research progress on 2,4-thiazolidinedione and 2-thioxo-4-thiazolidinone analogues as aldose reductase inhibitors. *Journal of Molecular Structure*, 2022; Volume 1269, art. Number: 133742 DOI: 10.1016/j.molstruc.2022.133742.
2. Bala C, Rusu A, Ciobanu D, Roman G. Length of Hospital Stay, Hospitalization Costs, and Their Drivers in Adults with Diabetes in the Romanian Public Hospital System. *Int J Environ Res Public Health.* 2022 Aug 14;19(16):10035. doi: 10.3390/ijerph191610035.
3. Kähm K, Laxy M, Schneider U, Holle R. Exploring Different Strategies of Assessing the Economic Impact of Multiple Diabetes-Associated Complications and Their Interactions: A Large Claims-Based Study in Germany. *Pharmacoeconomics.* 2019 Jan;37(1):63-74. doi: 10.1007/s40273-018-0699-1.
4. Overbeek JA, Heintjes EM, Huisman EL, Tikkanen CK, van Diermen AW, Penning-van Beest FJA, Herings RMC. Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes. *Diabetes Obes Metab.* 2018 Sep;20(9):2093-2102. doi: 10.1111/dom.13335.
5. Lathifah R, Ghofir A, Chalidyanto D, Yustiawan T. Number and Types of Complication in Type 2 Diabetes Correlated with Outpatient Treatment Cost Using BPJS Self-Funded Scheme in Islamic Hospital Jombang. In Proceedings of the 4th Annual Meeting of the Indonesian Health Economics Association (INAHEA 2017), pages 290-294. https://repository.unair.ac.id/116638/14/13_FullText%2026.pdf#page=309

6. Kodiattu SK. PHARMACOECONOMICS OF DIABETIC NEPHROPATHY MANAGEMENT IN A TERTIARY CARE HOSPITAL. Dissertation Submitted to the Rajiv Gandhi University of Health Sciences, Bangalore, Karnataka, 2018; <https://www.proquest.com/openview/d9b6edd694f7d1397d427a7b57fb2313/1?pq-origsite=gscholar&cbl=2026366&diss=y>

2016

47. Dimitrova, M., Tachkov, K., **Petrova, G.** Cost-effectiveness assessment of liver disease therapy in Bulgaria (2016) Journal of the Balkan Tribological Association, 22 (4-II), pp. 4146-4158.
48. VL Boyadzhieva, N Stoilov, R Stoilov, **G Petrova.** COST OF TREATMENT OF RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS WITH BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE PERIOD 2013-2014 IN BULGARIA. JOURNAL OF THE BALKAN TRIBOLOGICAL ASSOCIATION, 2016; 22 (1): 401-409
49. **Petrova, G.**, Benbassat, B., Lakic, D., Dimitrova, M., Mitov, K., Dimitrov, J. Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization (2016) Biotechnology and Biotechnological Equipment, 30 (3), pp. 614-621. Cited 1 time. DOI: 10.1080/13102818.2016.1160796
50. **Petrova G**, Doneva M, Mitkova Z, Tachkov K, Manova M. Generics and fixed-dose combinations in cardiology: Satisfaction analysis of pharmacists and cardiologists. Biotechnol Biotechnol Equip. 2016; 30(1): 204-11.

Цитирания:

1. Ковачка Г, Герасимов Н, Камушева М. ДОСТЪПНОСТ И РЕИМБУРСИРАНЕ НА ТЕРАПИЯТА С АНТИХИПЕРЛИПИДЕМИЧНИ ЛЕКАРСТВЕНИ ПРОДУКТИ В БЪЛГАРИЯ. Medical Review - Cardiovascular Diseases, 2020; Vol 51, Issue 2, p10, ISSN 0204-6865.
51. Jakubczyk M, Lipka I, Pawkska J, Niewada M, Rdzanek E, Zaletel J, Ramirez de Arellano A, Dolehal T, Chekova Mitreva B, Nagy B, **Petrova G**, Љариж Т, Yfantopoulos J, Czech M. Cost of severe hypoglycaemia in nine european countries. J Med Econ 2016;19(10):973-82.

Цитирания:

1. Shi L, Fonseca V, Childs B. Economic burden of diabetes-related hypoglycemia on patients, payors, and employers. J Diabetes

Complications. 2021 Jun;35(6):107916. doi: 10.1016/j.jdiacomp.2021.107916.

2. Soares AR, Coelho M, Tracey M, Carvalho D, Silva-Nunes J. Epidemiological, Social and Economic Burden of Severe Hypoglycaemia in Patients with Diabetes Mellitus in Portugal: A Structured Literature Review. *Diabetes Ther.* 2023 Feb;14(2):265-291. doi: 10.1007/s13300-022-01358-1.
3. Luengo-Fernandez R, Walli-Attaei M, Gray A, Torbica A, Maggioni AP, Huculeci R, Bairami F, Aboyans V, Timmis AD, Vardas P, Leal J. Economic burden of cardiovascular diseases in the European Union: a population-based cost study. *Eur Heart J.* 2023 Dec 1;44(45):4752-4767. doi: 10.1093/eurheartj/ehad583.
4. Lambadiari V, Ozdemir Saltik AZ, de Portu S, Buompensiere MI, Kountouri A, Korakas E, Sharland H, Cohen O. Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece. *Diabetes Technol Ther.* 2022 May;24(5):316-323. doi: 10.1089/dia.2021.0443.
5. Hellmund R, Weitgasser R, Blissett D. Cost calculation for a flash glucose monitoring system for UK adults with type 1 diabetes mellitus receiving intensive insulin treatment. *Diabetes Res Clin Pract.* 2018 Apr;138:193-200. doi: 10.1016/j.diabres.2018.01.028.
6. Gorgojo-Martínez JJ, Malkin SJP, Martín V, Hallén N, Hunt B. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. *J Med Econ.* 2020 Feb;23(2):193-203. doi: 10.1080/13696998.2019.1681436.
7. Núñez M, Díaz S, Dilla T, Reviriego J, Pérez A. Epidemiology, Quality of Life, and Costs Associated with Hypoglycemia in Patients with Diabetes in Spain: A Systematic Literature Review. *Diabetes Ther.* 2019 Apr;10(2):375-392. doi: 10.1007/s13300-019-0563-0.
8. Jendle J, Buompensiere MI, Ozdemir Saltik AZ, de Portu S, Smith-Palmer J, Pollock RF, Cohen O. A European Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes. *Diabetes Technol Ther.* 2023 Dec;25(12):864-876. doi: 10.1089/dia.2023.0297.
9. Martín V, Vidal J, Malkin SJP, Hallén N, Hunt B. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. *Adv Ther.* 2020 Oct;37(10):4427-4445. doi: 10.1007/s12325-020-01464-1.

10. Osumili B, Artime E, Mitchell B, Rubio-de Santos M, Díaz-Cerezo S, Giménez M, Spaepen E, Sharland H, Valentine WJ. Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain. *Diabetes Ther.* 2022 Apr;13(4):775-794. doi: 10.1007/s13300-022-01238-8.
11. Ampudia-Blasco FJ, Artime E, Díaz S, Rubio M, Reviriego J, Mitchell B, Osumili B, Peyrot M, Pokrzywinski R, Spaepen E, Snoek F. Conversations and Reactions Around Severe Hypoglycaemia (CRASH): Spanish results of a global survey of people with type 1 diabetes or insulin-treated type 2 diabetes and caregivers. *Endocrinol Diabetes Nutr (Engl Ed).* 2021 Oct;68(8):557-566. doi: 10.1016/j.endien.2021.11.012.
12. Gebremichael GB, Mariye Zemicheal T. Hypoglycemia Prevention Practice and Associated Factors among Diabetic Patients on Follow-Up at Public Hospitals of Central Zone, Tigray, Ethiopia, 2018. *Int J Endocrinol.* 2020 Mar 13;2020:8743531. doi: 10.1155/2020/8743531.
13. Haluzik M, Kretowski A, Strojek K, Czupryniak L, Janez A, Kempler P, Andel M, Tankova T, Boyanov M, Smircic Duvnjak L, Madacsy L, Tarnowska I, Zychma M, Lalic N. Perspectives of Patients with Insulin-Treated Type 1 and Type 2 Diabetes on Hypoglycemia: Results of the HAT Observational Study in Central and Eastern European Countries. *Diabetes Ther.* 2018 Apr;9(2):727-741. doi: 10.1007/s13300-018-0388-2.
14. Mönnig E, Spaepen E, Osumili B, Mitchell BD, Snoek F, Peyrot M, Kern W, Holstein A. Conversations and Reactions Around Severe Hypoglycaemia (CRASH): Results from the German Cohort of a Global Survey of People with Type 1 Diabetes or Insulin-Treated Type 2 Diabetes and Caregivers. *Exp Clin Endocrinol Diabetes.* 2022 Mar;130(3):145-155. doi: 10.1055/a-1310-7963.
15. Orozco-Beltrán D, Pineda AL, Quesada JA, Artime E, Díaz-Cerezo S, Redondo-Antón J, Santos MR, Spaepen E, Munuera MCC. Barriers and solutions for the management of severe hypoglycaemia in people with diabetes in Spain: A Delphi survey. *Prim Care Diabetes.* 2024 Feb;18(1):65-73. doi: 10.1016/j.pcd.2023.11.007.
16. Jermendy G, Kecskes A, Nagy A. Nocturnal Hypoglycaemia in Patients with Diabetes Mellitus: Database Analysis of a Cohort Using Telemedicine Support for Self-Monitoring of Blood Glucose over a 10-Year-Long Period. *Medicina (Kaunas).* 2021 Feb 14;57(2):167. doi: 10.3390/medicina57020167.
17. Le Pen C, Bauduceau B, Ansolabehere X, Troubat A, Bineau S, Ripert M, Dejager S. Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes.

Ann Endocrinol (Paris). 2021 Apr;82(2):99-106. doi: 10.1016/j.ando.2020.12.009.

18. Detournay B, Halimi S, Torreton E, Levy P. Cost of inpatient management of hypoglycemia in France among type 2 diabetes patients. *Médecine des Maladies Métaboliques*, 2017; Volume 11, Supplement 2, September 2017, Pages IIS16-IIS19 DOI: 10.1016/S1957-2557(18)30025-7.
19. Leiva-Gea I, Porcel Chacón R, Ariza Jiménez AB, Mora Loro M, Tapia-Ceballos L, Jiménez-Hinojosa J, Gómez Perea A, López Siguero JP. Impact on variables of severe hypoglycaemia and healthcare costs of the use of the FreeStyle system in paediatric population with type 1 diabetes mellitus. *Endocrinol Diabetes Nutr (Engl Ed)*. 2022 Oct;69(8):561-565. doi: 10.1016/j.endien.2021.10.011.
20. Beretzky Z. THE ROLE OF THE COST OF DISEASES AND QUALITY OF LIFE IN THE ALLOCATION OF HEALTHCARE RESOURCES. PH. D. THESIS. CORVINUS UNIVERSITY OF BUDAPEST. 2020; <https://core.ac.uk/download/pdf/328921616.pdf>
21. Alwafi H. The use and safety of oral anticoagulants in patients with type 2 diabetes mellitus in the UK. Doctoral thesis (Ph.D), UCL (University College London), 2021; <https://discovery.ucl.ac.uk/id/eprint/10122751/>
22. Valov V, Manova M, Savova A, Mitov K. COSTS FOR TREATMENT OF DIABETES: A LITERATURE REVIEW. *General medicine*, 2018; XX, 3, p 86-92.
23. Parekh W, Hoskins N, Knight JB, Arellano A, Raya PM. The Economic Burden of Insulin-Related Hypoglycemia in Spain. *Diabetes Therapy*, 2017; Volume 8, pages 899–913, DOI 10.1007/s13300-017-0285-0.
52. Mitkova Z, Vasileva M, Savova A, Manova M, **Petrova G**. Analysis of cardiovascular medicines prices and reimbursement in Bulgaria and Romania. *Revista Farmacia*. 2016;64(4):633-42. (IF 1.162)

Цитирания:

1. Nistor AL, Pisani E, Kok MO. Why falsified medicines reach patients: an analysis of political and economic factors in Romania. *BMJ Glob Health*. 2023 Feb;6(Suppl 3):e009918. doi: 10.1136/bmjgh-2022-009918.

2017

53. Ferrario, A., Arvja, D., Bochenek, T., Иатир, Т., Danky, D., Dimitrova, M., Fьrst, J., Greйиытл-Kuprijanov, I., Hoxha, I., Jakupi, A., Laidмде, E., Лцblovб, O., Mardare, I., Markovic-Pekovic, V., Meshkov, D., Novakovic, T., **Petrova, G.**, Pomorski, M., Tomek, D., Voncina, L., Haycox, A., Kanavos, P., Vella Bonanno, P., Godman, B. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications (2017) *PharmacoEconomics*, 35 (12), pp. 1271-1285. DOI: 10.1007/s40273-017-0559-4

Цитирования:

1. Shukar S, Zahoor F, Hayat K, Saeed A, Gillani AH, Omer S, Hu S, Babar ZU, Fang Y, Yang C. Drug Shortage: Causes, Impact, and Mitigation Strategies. *Front Pharmacol*. 2021 Jul 9;12:693426. doi: 10.3389/fphar.2021.693426.
2. Wenzl M, Chapman S. Performance-based managed entry agreements for new medicines in OECD countries and EU member states: how they work and possible improvements going forward. *OECD Health Working Papers*, 2019, No. 115, 97 doi: 10.1787/6e5e4c0f-en.
3. Dabbous M, Chachoua L, Caban A, Toumi M. Managed Entry Agreements: Policy Analysis From the European Perspective. *Value Health*. 2020 Apr;23(4):425-433. doi: 10.1016/j.jval.2019.12.008.
4. Vogler S, Paris V, Panteli D. Ensuring access to medicines: How to redesign pricing, reimbursement and procurement?. *European Observatory on Health Systems and Policies*, Copenhagen (Denmark); 2018. <https://pesquisa.bvsalud.org/portal/resource/pt/who-331972>.
5. Xoxi E, Facey KM, Cicchetti A. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy. *Front Pharmacol*. 2021 Aug 10;12:699466. doi: 10.3389/fphar.2021.699466.
6. Antonanzas F, Juárez-Castelló C, Lorente R, Rodríguez-Ibeas R. The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments. *Pharmacoeconomics*. 2019 Dec;37(12):1469-1483. doi: 10.1007/s40273-019-00838-w.
7. Pérez-Ríos M, Rey-Brandariz J, Galán I, Fernández E, Montes A, Santiago-Pérez MI, Giraldo-Osorio A, Ruano-Raviña A. Methodological guidelines for the estimation of attributable mortality using a prevalence-based method: the STREAMS-P tool. *J Clin Epidemiol*. 2022 Jul;147:101-110. doi: 10.1016/j.jclinepi.2022.03.016.
8. Scavone C, di Mauro G, Mascolo A, Berrino L, Rossi F, Capuano A. The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs. *Front Pharmacol*. 2019 Feb 13;10:111. doi: 10.3389/fphar.2019.00111.
9. Gamba S, Pertile P, Vogler S. The impact of managed entry agreements on pharmaceutical prices. *Health Econ*. 2020 Oct;29 Suppl 1:47-62. doi: 10.1002/hec.4112.
10. Mela A, Poniatowski ŁA, Drop B, Furtak-Niczyporuk M, Jaroszyński J, Wrona W, Staniszevska A, Dąbrowski J, Czajka A, Jagielska B, Wojciechowska M, Niewada M. Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic

Diseases Related Drug Therapies from 2015-2018 Years. *Front Pharmacol.* 2020 Aug 14;11:1123. doi: 10.3389/fphar.2020.01123.

11. Rejon-Parrilla JC, Espin J, Garner S, Kniazkov S, Epstein D. Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries. *Front Pharmacol.* 2023 Nov 28;14:1199500. doi: 10.3389/fphar.2023.1199500.
12. Vogler S, Schneider P, Zimmermann N. Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing. *Pharmacoecoon Open.* 2019 Sep;3(3):303-309. doi: 10.1007/s41669-019-0120-9.
13. Vogler S. Can we achieve affordable cancer medicine prices? Developing a pathway for change. *Expert Rev Pharmacoecon Outcomes Res.* 2021 Jun;21(3):321-325. doi: 10.1080/14737167.2021.1898951.
14. Callenbach MHE, Ádám L, Vreman RA, Németh B, Kaló Z, Goettsch WG. Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook. *Drug Discov Today.* 2023 Jan;28(1):103433. doi: 10.1016/j.drudis.2022.103433.
15. Kwon HY, Bae S, Choi SE, Park S, Lee EK, Park S, Kim J. Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea. *Health Policy.* 2019 Apr;123(4):388-392. doi: 10.1016/j.healthpol.2018.11.002.
16. Hospodková P, Gilíková K, Barták M, Marušáková E, Tichopád A. Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective. *Healthcare (Basel).* 2023 Apr 19;11(8):1179. doi: 10.3390/healthcare11081179.
17. Wettstein DJ, Boes S. Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review. *Appl Health Econ Health Policy.* 2019 Apr;17(2):143-162. doi: 10.1007/s40258-018-0437-z.
18. Vogler S. Prices of new medicines: International analysis and policy options. *Z Evid Fortbild Qual Gesundheitsw.* 2022 Dec;175:96-102. doi: 10.1016/j.zefq.2022.09.009.
19. Ádám I, Callenbach M, Németh B, Vreman RA, Pontén J, Strbad T, Dawoud D, Kostyuk A, Seyam A, Nagy L, Goettsch WG, Kaló Z. Delayed payment schemes in Central-Eastern Europe and Middle-East. *Front Med (Lausanne).* 2022 Aug 12;9:940371. doi: 10.3389/fmed.2022.940371.

20. Russo P, Marcellusi A, Zanuzzi M, Carletto A, Fratto ME, Favato G, Staniscia T, Romano F. Drug Prices and Value of Oncology Drugs in Italy. *Value Health*. 2021 Sep;24(9):1273-1278. doi: 10.1016/j.jval.2021.04.1278.
21. Németh B, Csanádi M, Inotai A, Ameyaw D, Kaló Z. Access to High-Priced Medicines in Lower-Income Countries in the WHO European Region [Internet]. Copenhagen , Denmark: World Health Organization; 2022. PMID: 36542735. <https://iris.who.int/handle/10665/361751>.
22. Bade C, Olsacher A, Boehme P, Truebel H, Fehring L. Reasons for supply side driven drug shortages - A mixed-methods study on first-level, higher-level, and root causes from the perspective of marketing authorization holders. *Res Social Adm Pharm*. 2023 Aug;19(8):1218-1227. doi: 10.1016/j.sapharm.2023.05.007.
23. Guarga L, Gasol M, Reyes A, Roig M, Alonso E, Clopés A, Delgadillo J. Implementing Risk-Sharing Arrangements for Innovative Medicines: The Experience in Catalonia (Spain). *Value Health*. 2022 May;25(5):803-809. doi: 10.1016/j.jval.2021.10.010.
24. AlAzmi A, AlRashidi F. Medication Exchange and Sharing Network Program (MESNP) initiative to cope with drug shortages in the Kingdom of Saudi Arabia (KSA). *Risk Manag Healthc Policy*. 2019 Jul 9;12:115-121. doi: 10.2147/RMHP.S198375.
25. Zaric GS. How Risky Is That Risk Sharing Agreement? Mean-Variance Tradeoffs and Unintended Consequences of Six Common Risk Sharing Agreements. *MDM Policy Pract*. 2021 Feb 9;6(1):2381468321990404. doi: 10.1177/2381468321990404.
26. Al-Omar HA, Attuwaijri AA, Aljuffali IA. Pharmaceutical companies' views on a health technology assessment (HTA) entity in Saudi Arabia. *Saudi Pharm J*. 2020 Jun;28(6):662-668. doi: 10.1016/j.jsps.2020.04.006.
27. Vogler S. Payer Policies to Support Innovation and Access to Medicines in the WHO European Region [Internet]. Copenhagen Ø, Denmark: World Health Organization; 2022. PMID: 36542740. <https://iris.who.int/handle/10665/361753>
28. Vogler S, Schneider P, Lepuschütz L. Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation. *Cost Eff Resour Alloc*. 2020 Nov 16;18(1):51. doi: 10.1186/s12962-020-00247-3.
29. Tuffaha HW, Scuffham PA. The Australian Managed Entry Scheme: Are We Getting it Right? *Pharmacoeconomics*. 2018 May;36(5):555-565. doi: 10.1007/s40273-018-0633-6.

30. Stevens B, Kenny T, Thomas S, Morrison A, Jarrett J, Jain M. Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement. *Orphanet J Rare Dis.* 2021 Sep 25;16(1):394. doi: 10.1186/s13023-021-01876-4.
31. Aguiar P Jr, Giglio AD, Perry LA, Penny-Dimri J, Babiker H, Tadokoro H, Lopes G Jr, De Mello RA. Cost-effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access. *Immunotherapy.* 2018 Aug;10(10):887-897. doi: 10.2217/imt-2017-0183.
32. Wettstein DJ, Boes S. How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence. *Health Policy.* 2022 Feb;126(2):112-121. doi: 10.1016/j.healthpol.2021.12.007.
33. Vogler S. Access to Information in Markets for Medicines in the WHO European Region [Internet]. Copenhagen Ø, Denmark: World Health Organization; 2022. <https://www.ncbi.nlm.nih.gov/books/NBK587895/>
34. Ispán F, Hegedüs T, Csanádi M, Nagy B. Goals and methods of managed entry agreements—can we get what we want?. *Health Policy and Technology*,2023; 12(2), 100745. doi: 10.1016/j.hlpt.2023.100745.
35. Patikorn C, Taychakhoonavudh S, Sakulbumrungsil R, Ross-Degnan D, Anantachoti P. Financing Strategies to Facilitate Access to High-Cost Anticancer Drugs: A Systematic Review of the Literature. *Int J Health Policy Manag.* 2022 Sep 1;11(9):1625-1634. doi: 10.34172/ijhpm.2021.138.
36. Inotai A, Kaló Z. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways. *Expert Rev Pharmacoecon Outcomes Res.* 2019 Dec;19(6):627-632. doi: 10.1080/14737167.2019.1702524.
37. Darbà J, Ascanio M. The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia. *Expert Rev Pharmacoecon Outcomes Res.* 2019 Dec;19(6):743-748. doi: 10.1080/14737167.2019.1587296.
38. Fens T, van Puijenbroek EP, Postma MJ. Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy. *Front Med Technol.* 2021 Apr 28;3:629750. doi: 10.3389/fmedt.2021.629750.
39. Castro HE, Malpica T, Musila R, Konduri N, Amaris A, Sullivan J, Gilmartin C. Sharing knowledge for policy action in low- and middle-income countries:

A literature review of managed entry agreements. *The Journal of Medicine Access. Point of care*, 2019; Volume 3; doi: 10.1177/2399202619834246.

40. Callenbach MHE, Vreman RA, Mantel-Teeuwisse AK, Goettsch WG. When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs. *Int J Environ Res Public Health*. 2022 Dec 26;20(1):340. doi: 10.3390/ijerph20010340.
41. Reyes-Travé A, Guarga-Solé L, Roig-Izquierdo M, Alonso-Pérez E, Clopés-Estela A, Delgadillo-Duarte J. Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia. *Pharmacoeconomics*. 2021 Sep;39(9):973-982. doi: 10.1007/s40273-021-01046-1.
42. Kim S, Kim J, Cho H, Lee K, Ryu C, Lee JH. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years. *Expert Rev Pharmacoecon Outcomes Res*. 2021 Jun;21(3):479-488. doi: 10.1080/14737167.2021.1860023.
43. Thanimalai S, Choon WY, Lee KK. Stakeholder views of managed entry agreements: A literature review of national studies. *Health Policy Open*. 2021 Jan 21;2:100032. doi: 10.1016/j.hopen.2021.100032.
44. Nabulsi NA, Martin MT, Sharp LK, Koren DE, Teply R, Zuckerman A, Lee TA. Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy. *Front Pharmacol*. 2020 Nov 13;11:551500. doi: 10.3389/fphar.2020.551500.
45. Vogler S, Windisch F. Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections-Overview of Policies Applied in 17 European Countries. *Antibiotics (Basel)*. 2022 Jul 22;11(8):987. doi: 10.3390/antibiotics11080987.
46. Vogler S. Medicines Pricing: Limitations of Existing Policies and New Models. In: *Global Pharmaceutical Policy*. Palgrave Macmillan, Singapur, 2020, g/10.1007/978-981.
47. Mahlich J, Sindern J, Suppliet M. Cross-national drug price comparisons with economic weights in external reference pricing in Germany. *Expert Rev Pharmacoecon Outcomes Res*. 2019 Feb;19(1):37-43. doi: 10.1080/14737167.2019.1527221.
48. McMullan P, Ajay VS, Srinivas R, Bhalla S, Prabhakaran D, Banerjee A. Improving access to medicines via the Health Impact Fund in India: a

- stakeholder analysis. *Glob Health Action*. 2018;11(1):1434935. doi: 10.1080/16549716.2018.1434935.
49. Hospodková P, Karásek P, Tichopád A. Stakeholder Insights into Czech Performance-Based Managed Entry Agreements: Potential for Transformative Change in Pharmaceutical Access? *Healthcare (Basel)*. 2024 Jan 4;12(1):119. doi: 10.3390/healthcare12010119.
 50. Cho E, Yoo SL, Kang Y, Lee JH. Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement. *Regen Med*. 2020 Apr;15(4):1550-1560. doi: 10.2217/rme-2020-0035.
 51. BIANCALANI F, GNECCO G, RICCABONI M. Price-volume agreements: a one principal/two agents model. *European Journal of Operational Research*, 2022, vol. 300, issue 1, 296-309. DOI: 10.1016/j.ejor.2021.10.050.
 52. Al-Omar HA, Alghannam HH, Aljuffali IA. Exploring the status and views of managed entry agreements in Saudi Arabia: mixed-methods approach. *Expert Rev Pharmacoecon Outcomes Res*. 2021 Aug;21(4):837-845. doi: 10.1080/14737167.2020.1792295.
 53. García-Collado CG, Martínez-de-la-Plata JE, Montoro MDMM, Morales AJ, Hernández MÁC, Martínez FM. Impact of a risk-sharing agreement in rheumatoid arthritis in Spain. *Health Policy*. 2021 Mar;125(3):335-340. doi: 10.1016/j.healthpol.2020.11.009.
 54. Buyukkaramikli NC, Wigfield P, Hoang MT. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England. *Eur J Health Econ*. 2021 Feb;22(1):51-73. doi: 10.1007/s10198-020-01228-2.
 55. Tordrup D, van den Ham R, Leopold C, Joosse I, Glanville J, Kotas E, Mantel-Teeuwisse A. Systematic reviews for the update of the WHO Guideline on country pharmaceutical pricing policies. In WHO guideline on country pharmaceutical pricing policies [Internet]. (2020) World Health Organization. <https://www.ncbi.nlm.nih.gov/books/NBK570141/>
 56. Mundy L, Trowman R, Kearney B. Improving Access to High-Cost Technologies in the Asia Region. *Int J Technol Assess Health Care*. 2019 Jan;35(3):168-175. doi: 10.1017/S026646231900031X.
 57. Jakovljevic M, Yamada T. Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies. *Front Pharmacol*. 2017 Sep 21;8:662. doi: 10.3389/fphar.2017.00662.

58. Alkhatib NS, Slack M, Bhattacharjee S, Erstad B, Ramos K, McBride A, Abraham I. Pricing methods in outcome-based contracting: 66: adherence-based pricing. *J Med Econ.* 2020 Nov;23(11):1256-1265. doi: 10.1080/13696998.2020.1815030.
59. Gasperoni L, Cafaro A, Ferretti E, Di Iorio V, Nanni O, Masini C. The role of clinical trials in the sustainability of the Italian national health service cancer drug expenditure. *Eur J Hosp Pharm.* 2023 Mar;30(2):96-100. doi: 10.1136/ejhpharm-2022-003297.
60. Peng JY, Lee SS, Lin CR, Lee H, Chen YC. Examining the Impact of the Current Reimbursement Regulation on Patient Access to Innovative Medical Devices in Taiwan: Insights From 8 Years' Reimbursement Data. *Value Health Reg Issues.* 2024 Feb 12;42:18-25. doi: 10.1016/j.vhri.2023.12.009.
61. RADU CP, DRĂGOI L, UDROIU MA, PANĂ BC, ILIESCU MC. THE OUTCOMES OF MANAGED ENTRY AGREEMENTS IN ROMANIA FROM 2015 TO 2022. *Farmacia*, 2023, Vol 71, Issue 6, p1316; DOI 10.31925/farmacia.2023.6.23.
62. ARAJA D. INSIGHTS INTO TRENDS AND CHALLENGES OF THE PHARMACEUTICAL INDUSTRY: THE ROLE OF SCIENTIFIC BUSINESS RESEARCH. *Journal of Business Management*, 2023, Vol 21, p48. DOI 10.32025/JBM23002
63. Catic T, Zunic L. How Bosnia and Herzegovina Can Benefit from Health Technology Assessment. *Int J Biomed Healthc.* 2022; 10(1): 57-61. , doi: 10.5455/ijbh.2022.10.57-61.
64. Abu-Shraie N, Alhammad A, Balkhi B, Al-Jedai A . Implementation of risk-sharing agreements in Saudi Arabia: Comparison and reflection on the NICE Model. *Tropical Journal of Pharmaceutical Research*, 2023; 22(5), 1121-1131. DOI 10.4314/tjpr.v22i5.27.
65. Zaliska OM, Stasiv KO. Scientific methodology and practical use of managed entry agreements for innovative medicines in system of health technology assessment in Ukraine. *Farmatsevtichnyi zhurnal*, 2019; (4), 32-40. DOI: 10.32352/0367-3057.4.19.04.
66. Fens T, Postma M. Innovative medicines & managed entry agreements; a happy marriage?. *Macedonian Pharmaceutical Bulletin*, 2020; 66, 59-60. DOI: 10.33320/maced.pharm.bull.2020.66.03.029.
67. Lučić S, Pokvić LG, Bečić E, Badnjević A. Health Sector Pricing and financing models: Challenges and pharmacoeconomic trends in Bosnia and Herzegovina. In *International Conference on Medical and Biological Engineering*, 2021 (pp. 547-553). Cham: Springer International Publishing.

68. Fedorov V, Kravchenko S, Reznichenko H, Opara N, Tsybokhin O. Theoretical problems of legal regulation of innovations in the medical field: experience in counteracting covid-19. *Ius Humani. Revista de Derecho*, 2020; 9(2), 251-289. DOI 10.31207/ih.v9i2.254.
69. Gilíková K, Hospodková P, Tichopád A. Threats and Opportunities Associated with the Implementation of Performance based Managed Entry Agreements in Slovakia. The 10th IEEE International Conference on E-Health and Bioengineering - EHB 2022, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania, November 17-18, 2022.
70. Paveliu MS, Radu C.P, Pana BC. Confidentiality in the Pharmaceutical Managed Entry Agreements in Romania. *RJMM*, 2024, vol. CXXVII, 3, part-7, pp: 222-227.
71. Shobeiri N, Peiravian F, Yousefi N. How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements? *Iran J Pharm Res*. 2022 May 4;21(1):e126916. doi: 10.5812/ijpr-126916.
72. Aguiar PN. Cost-effectiveness and affordability of anticancer treatment in Brazil. *Ecancermedicallscience*. 2020 Jan 20;14:ed96. doi: 10.3332/ecancer.2020.ed96.
73. Дачева А, Джамбазов С, Славчев Г, Веков Т, Колев Ж. ВИДОВЕ СПОРАЗУМЕНИЯ ЗА СПОДЕЛЯНЕ НА РИСКА-ПРЕДИМСТВА И НЕДОСТАТЪЦИ, ПРИЛОЖЕНИЕ В ЦЕНТРАЛНА И ИЗТОЧНА ЕВРОПА. *General Medicine / Obsta Medicina*, 2020, Vol 22, Issue 2, p72.
74. Bayard JK, Gretsck K, Hallal Z, Stojkovic NS, Strydom J . PHP352-SUCCESS FACTORS FOR THE IMPLEMENTATION OF MARKET ACCESS AGREEMENTS IN EMERGING MIDDLE-INCOME MARKETS IN PREPARATION FOR OUTCOMES BASED CONCEPTS. *Value in Health*, 2018; 21,3, S210.
75. Markovic BS, Milosavljevic N, Arsenijevic A, Gazdic M, Lukic ML, Volarevic V. Bacterial flora play important roles in acute dextran sulphate sodium-induced colitis but are not involved in Gal-3 dependent modulation of colon inflammation. *Experimental and Applied Biomedical Research (EABR)*, 2017; 18(3), 213-220. DOI: 10.1515/sjecr-2017-0022..
54. Kawalec, P., Stawowczyk, E., Tesar, T., Skoupa, J., Turcu-Stiolica, A., Dimitrova, M., **Petrova G.I.**, Rugaja, Z., Мднник, А., Harsanyi, A., Draganic, P. Pricing and reimbursement of biosimilars in central and Eastern European countries (2017) *Frontiers in Pharmacology*, 8 (JUN), art. no. 288. DOI: 10.3389/fphar.2017.00288

Цитирания:

1. Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on

Pharmaceutical Expenditure. *Front Pharmacol.* 2021 Jun 25;12:625296. doi: 10.3389/fphar.2021.625296.

2. Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? *Front Pharmacol.* 2019 Mar 28;10:279. doi: 10.3389/fphar.2019.00279.
3. Dutta B, Huys I, Vulto AG, Simoens S. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! *BioDrugs.* 2020 Apr;34(2):159-170. doi: 10.1007/s40259-019-00395-w.
4. Blackwell K, Gligorov J, Jacobs I, Twelves C. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. *Clin Breast Cancer.* 2018 Apr;18(2):95-113. doi: 10.1016/j.clbc.2018.01.006.
5. Simoens S, Vulto AG. A health economic guide to market access of biosimilars. *Expert Opin Biol Ther.* 2021 Jan;21(1):9-17. doi: 10.1080/14712598.2021.1849132.
6. Carrascosa JM, Jacobs I, Petersel D, Strohal R. Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. *Dermatol Ther (Heidelb).* 2018 Jun;8(2):173-194. doi: 10.1007/s13555-018-0230-9.
7. De Ridder L, Assa A, Bronsky J, Romano C, Russell RK, Afzal NA, Hauer AC, Knafelz D, Lionetti P, Strisciuglio C, Veres G, Winter H, Wolters VM, Sladek M, Vulto AG, Dias JA; Paediatric IBD Porto group of ESPGHAN. Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN. *J Pediatr Gastroenterol Nutr.* 2019 Jan;68(1):144-153. doi: 10.1097/MPG.0000000000002141.
8. Włodarczyk SR, Custódio D, Pessoa A Jr, Monteiro G. Influence and effect of osmolytes in biopharmaceutical formulations. *Eur J Pharm Biopharm.* 2018 Oct;131:92-98. doi: 10.1016/j.ejpb.2018.07.019.
9. Larid G, Baudens G, Dandurand A, Coquerelle P, Goeb V, Guyot MH, Marguerie L, Maury F, Veillard E, Houvenagel E, Salmon JH, Flipo RM, Gervais E. Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study. *Front Med (Lausanne).* 2022 Oct 6;9:989514. doi: 10.3389/fmed.2022.989514.
10. De Corso E, Furneri G, Salsi D, Fanelli F, Ronci G, Sala G, Bitonti R, Cuda D. Cost-Utility Analysis of Dupilumab for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Italy. *J Pers Med.* 2022 Jun 10;12(6):951. doi: 10.3390/jpm12060951.

11. Simoens S, Cheung R. Tendering and biosimilars: what role for value-added services? *J Mark Access Health Policy*. 2019 Dec 22;8(1):1705120. doi: 10.1080/20016689.2019.1705120.
12. Moorkens E, Lacosta TB, Dawoud D, Inotai A, Janodia M, Tan CJ, Lim KK, Khatri N, Pereira CL, Simoens S. A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report. *Value Health*. 2023 Aug;26(8):1137-1144. doi: 10.1016/j.jval.2023.04.007.
13. Inotai A, Tomek D, Niewada M, Lorenzovici L, Kolek M, Weber J, Kurrat AK, Kiss EV, Kaló Z. Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries. *Front Pharmacol*. 2020 Jun 5;11:845. doi: 10.3389/fphar.2020.00845.
14. Vulto AG, Vanderpuye-Orgle J, van der Graaff M, Simoens SRA, Dagna L, Macaulay R, Majeed B, Lemay J, Hippenmeyer J, Gonzalez-McQuire S. Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review. *Pharmaceuticals (Basel)*. 2020 Nov 17;13(11):400. doi: 10.3390/ph13110400.
15. Rezk MF, Pieper B. Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. *Adv Ther*. 2020 Sep;37(9):3732-3745. doi: 10.1007/s12325-020-01437-4.
16. Machado S, Cruz A, Ferreira PL, Morais C, Pimenta RE. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review. *Frontiers in Public Health*;2024; 12, 1263472. DOI: 10.3389/fpubh.2024.1263472.
17. Maksabedian Hernandez EJ, Graf M, Portelli A, Shafrin J. Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators. *J Med Econ*. 2022 Jan-Dec;25(1):1118-1126. doi: 10.1080/13696998.2022.2113252.
18. Shin G, Kim BS, Kim DY, Bae S. Unveiling the Biosimilar Paradox of Oncologists' Perceptions and Hesitations in South Korea: A Web-Based Survey Study. *BioDrugs*. 2024 Mar;38(2):301-311. doi: 10.1007/s40259-023-00640-3.
19. Sarzi-Puttini P, Marotto D, Caporali R, Galeazzi M, Atzeni F, Hamar A, Soós B, Szekanecz Z. Biosimilars vs originators: Are they the same? *Autoimmun Rev*. 2019 Dec;18(12):102404. doi: 10.1016/j.autrev.2019.102404.

20. Peng K, Blais JE, Pratt NL, Guo JJ, Hillen JB, Stanford T, Ward M, Lai EC, Shin JY, Tong X, Fan M, Cheng FWT, Wu J, Yeung WWY, Lau CS, Leung WK, Wong ICK, Li X. Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis. *BioDrugs*. 2023 May;37(3):409-420. doi: 10.1007/s40259-023-00589-3.
21. Martínez González J, Monreal M, Ayani Almagia I, Llaudó Garín J, Ochoa Díaz de Monasterioguren L, Gutierrez Adúriz I. Bioequivalence of a biosimilar enoxaparin sodium to Clexane® after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers. *Drug Des Devel Ther*. 2018 Mar 19;12:575-582. doi: 10.2147/DDDT.S162817.
22. Fasseeh AN, Elezbawy B, El-Fass KA, Gamal M, Seyam A, Hayek N, Abdel Rahman N, Abdelhamid S, Fasseeh N, Saad AS, Elagamy A, Mahmoud A, Sedrak AS, Elshazly K, Eldebeiky M, Talaat M, Mohamed NM, Abdelaziz RA, Refaat R, Akeel S, Abaza S, Kaló Z. Maximizing the benefits of using biosimilars in Egypt. *J Pharm Policy Pract*. 2023 Jun 26;16(1):79. doi: 10.1186/s40545-023-00581-w.
23. Hornyák L, Nagy Z, Ilku L, Tálos Z, Endrei D, Ágoston I, Csákvári T, Danku N, Répásy B, Boncz I. Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary. *Expert Rev Pharmacoecon Outcomes Res*. 2019 Dec;19(6):725-731. doi: 10.1080/14737167.2019.1582334.
24. Trapani D, Curigliano G, Eniu A. Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems. *Breast Care (Basel)*. 2019 Dec;14(6):373-381. doi: 10.1159/000502637.
25. Gandhi S, Kashiramka S, Rathore AS. Emerging themes and factors influencing the prices of biotherapeutics. *World Medical & Health Policy*, 2023; 15(4), 613-637. doi: 10.1002/wmh3.571.
26. Sharma A, Khante S, Mahadik KR, Gaikwad VL. Regulatory Perspective of International Agencies for Development of Biosimilar Products (Monoclonal Antibodies): An Overview. *Ther Innov Regul Sci*. 2020 Sep;54(5):965-977. doi: 10.1007/s43441-020-00112-8.
27. Tolkacheva DG, Torgov AV, Margazova AS. International approaches to the government price control over generics and biosimilars: a review. *FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology*, 2018; 10(4), 15-24.. DOI: 10.17749/2070-4909.2017.10.4.015-024.

28. Елсукова ОС. ИСПОЛЬЗОВАНИЕ РЕКОМЕНДАЦИЙ CARE ДЛЯ ОПИСАНИЯ СЛУЧАЕВ ИЗ ПРАКТИКИ ВРАЧА. РМЖ, 2023; (2), 16-24..
29. Chakuleska L, Simeonova R, Danchev N. Pharmacotherapy costs and medicines reimbursement policies of osteoporosis in the Republic of Bulgaria and Republic of North Macedonia. *Pharmacia* (0428-0296), 2020, Vol 67, Issue 4, p199. DOI 10.3897/pharmacia.67.e55835.
30. Demidova TY, Titova VV, Saverskaya EN. Biosimilars: new era of pharmacology. What is interesting about insulin biosimilars. *FOCUS Endocrinology*. 2021; 3: 39–47. DOI: 10.47407/ef2021.2.3.0033.
31. Barszczewska O. DRUG POLICY AS PART OF SOCIAL POLICY-CHALLENGES AND SYSTEMIC SOLUTIONS USING THE EXAMPLE OF THE DISSEMINATION OF BIOSIMILAR MEDICINES, EUROPEAN LITERATURE REVIEW. *Polityka Społeczna*, 2023; 592(8), 17-24. DOI: 10.5604/01.3001.0053.9025.
32. Schneider P, Vogler S. Price studies for specific medicines. *Medicine Price Surveys. Analyses and Comparisons*, 2019; 113-164. doi: 10.1016/B978-0-12-813166-4.00008-5.
33. Булгакова СВ, Саверская ЕН, Шаронова ЛА, Долгих ЮА, Косарева ОВ. Биосимиляр аналога инсулина гларгин: доказанная безопасность, эффективность, взаимозаменяемость. *Медицинский совет*, 2022; 16(23), 207-214. DOI: 10.21518/2079-701X-2022-16-23-207-214
34. Саверская ЕН, Елтышева ТЭ, Карпов ДС, Коробкина МП, Заикин ПГ. Применение биосимиляров инсулиновых аналогов аспарт и лизпро в помпе. *"Русский Медицинский Журнал"*, 2022; 1, 9-14.
35. Grigoriev V, Valica V, Cazacu R, Cazacu V, Rusnac L . Perspectives of rhGH biosimilar research and manufacturing in Republica Moldova. *Revista Farmaceutică a Moldovei*. 2021, vol. 45, nr. 1, pp. 16-20. ISSN 1812-5077
36. PACZKOWSKA A, KUS K, KOPCIUCH D , ZAPRUTKO T , STACHOWIAK Z , RATAJCZAK P, NOWAKOWSKA E. SAFETY OF BIODRUGS- PHARMACISTS' KNOWLEDGE AND PRACTICE WITH REGARD TO POLISH AND EUROPEAN LEGAL ASPECTS AND SUBSTITUTION OF BIOTECHNOLOGY DRUGS: MULTICENTER STUDY IN POLAND. *Acta Poloniae Pharmaceutica- Drug Research*, 2020; Vol. 77 No. 4 pp. 657- 664 DOI: 10.32383/appdr/127257.
37. Ukoma CT, Nna EO, Okoye HC, et al. Effectiveness, Uses and Safety of Granulocyte Colony Stimulating Factor biosimilars: a protocol for systematic review and meta-analysis. *Research Square*; 2021. DOI: 10.21203/rs.3.rs-195467/v1. PPR: PPR277863.

38. Ziaie S, Malekmohammadi H, Sistanizad M. Comparison of Generic (Rolexan) and Brand (Clexan) Forms of Enoxaparin in Critically Ill Patients: A Cross Over, Open Label, Randomized Prospective Clinical Trial. *Journal of Pharmaceutical Care*, 2020; Volume (8) issue (1), 23-25. DOI: doi: 10.18502/jpc.v8i1.2743.
39. Georgieva S. Health technology assessment of biotechnology medicines with focus on hospital pharmacy. *International Journal of Biotech Trends and Technology (IJBTT)*, 2020; Volume 10 Issue 2; p:16-19. DOI:10.14445/22490183/IJBTT-V10I2P603 .
40. Więckowski Z . Is the Compulsory Licensing Mechanism Guaranteed by TRIPS the Best Remedy to Improve Access to Biological Therapies Worldwide?. *Eastern European Journal of Transnational Relations*,2019; 3(1), 39-52. DOI:10.15290/eejtr.2019.03.01.03
41. Szekanecz Z. Biosimilars: To switch or not to switch—that is the question. *Reumatologia/Rheumatology*, 2020; 58(1), 1-3. DOI: doi: 10.5114/reum.2020.93111.
55. Benbassat, B., Mitov, K., Savova, A., Tachkov, K., **Petrova, G.** Cost-effectiveness of different types of COH protocols for in vitro fertilization at national level (2017) *Biotechnology and Biotechnological Equipment*, 31 (1), pp. 206-214. DOI: 10.1080/13102818.2016.1261636

Цитирания:

1. ZALISKA O, STASIV K, MAKSYMOVYCH N, HRYNKIV Y. THE TRENDS OF ASSISTED REPRODUCTIVE TECHNOLOGIES AND COST FOR OVARIAN STIMULATION PROTOCOLS IN UKRAINE. *Pharmacia* ,2020; 67(4): 269–276 DOI 10.3897/pharmacia.67.e55159.
2. Souza TO, Ben ÂJ, Dongen JMV, Bosmans JE, Cunha-Filho JSLD. Effectiveness and Cost-effectiveness of Minimal Ovarian Stimulation in-vitro Fertilization versus Conventional Ovarian Stimulation in Poor Responders: Economic Evaluation Alongside a Propensity Score Adjusted Prospective Observational Study. *JBRA Assist Reprod*. 2023 Jun 22;27(2):204-214. doi: 10.5935/1518-0557.20220025.
3. HUANG T, CHI Y, HE P, HUANG G, ZUO Y. Cost-effectiveness Analysis of GnRH Antagonist Protocol and Short-acting GnRH Agonist Long Protocol in Fresh Embryo Transfer Based on Propensity Score Matching. *Chinese General Practice*, 2023; Vol. 26 » Issue (30): 3809-3814.DOI: 10.12114/j.issn.1007-9572.2022.0871.
4. Zaliska O, Stasiv K, Maksymovych N, Hrynkiv Y. The trends of assisted reproductive technologies and cost for ovarian stimulation protocols in Ukraine. *Pharmacia*,2020; 67(4): 269–276 DOI 10.3897/pharmacia.67.e55159.

5. Shtereva-Tzuni D, Naseva E. The nature and use of economic analysis in conducting research. *General Medicine*, 2020, 22 (5): 100-104.
56. Maria Dimitrova, Kaloyan Pavlov, Konstantin Mitov, Jordan Genov, **Guenka Ivanova Petrova**. Chronic hepatitis c-related cirrhosis hospitalization cost analysis in Bulgaria. *Frontiers in medicine* 2017; 4: 12

Цитирания:

1. Tan J, Tang X, He Y, Xu X, Qiu D, Chen J, Zhang Q, Zhang L. In-patient Expenditure Between 2012 and 2020 Concerning Patients With Liver Cirrhosis in Chongqing: A Hospital-Based Multicenter Retrospective Study. *Front Public Health*. 2022 Mar 8;10:780704. doi: 10.3389/fpubh.2022.780704.
 2. Vergara M, Miquel M, Vela E, Cleries M, Pontes C, Prat A, Rué M. Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents. *J Viral Hepat*. 2021 May;28(5):728-738. doi: 10.1111/jvh.13479.
57. Kamusheva M, Dimitrova M, van Boven JF, Postma MJ, van der Molen T, Kocks JW, Mitov K, Doneva M, Petrova D, Georgiev O, Petkova V, **Petrova G**. Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. *J Med Econ*. 2017 May;20(5):503-509. doi: 10.1080/13696998.2017.1279620.

Цитирания:

1. Valipour A, Aisanov Z, Avdeev S, Koblizek V, Kocan I, Kopitovic I, Lupkovics G, Man M, Bukovskis M, Tudoric N, Vukoja M, Naumnik W, Yanev N. Recommendations for COPD management in Central and Eastern Europe. *Expert Rev Respir Med*. 2022 Feb;16(2):221-234. doi: 10.1080/17476348.2021.2023498.
2. Czira A, Purushotham S, Iheanacho I, Rothnie KJ, Compton C, Ismaila AS. Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review. *Int J Chron Obstruct Pulmon Dis*. 2023 Apr 29;18:719-731. doi: 10.2147/COPD.S394325.
3. Stafyla E, Geitona M, Kerenidi T, Economou A, Daniil Z, Gourgoulialis KI. The annual direct costs of stable COPD in Greece. *Int J Chron Obstruct Pulmon Dis*. 2018 Jan 15;13:309-315. doi: 10.2147/COPD.S148051.
4. Pham HQ, Pham KHT, Ha GH, Pham TT, Nguyen HT, Nguyen THT, Oh JK. Economic burden of chronic obstructive pulmonary disease: A systematic review. *Tuberc Respir Dis (Seoul)*. 2024 Feb 16. doi: 10.4046/trd.2023.0100.

5. Kourlaba G, Hillas G, Vassilakopoulos T, Maniadakis N. The Economic Burden of Chronic Obstructive Pulmonary Disease in Greece. *Appl Health Econ Health Policy*. 2019 Feb;17(1):111-121. doi: 10.1007/s40258-018-0431-5.
 6. Hodzhev VA, Kenderov AN, Ivanov YY, Gospodinova-Vulkova DP, Kalinov K. Assessment of extrafine beclomethasone/formoterol for the treatment of chronic obstructive pulmonary disease: A non-interventional study in a Bulgarian population. *Pulm Pharmacol Ther*. 2022 Dec;77:102169. doi: 10.1016/j.pupt.2022.102169.
 7. Ivanov Y, Nikolaev I, Nemeth I. Real-life evaluation of COPD treatment in a Bulgarian population: a 1-year prospective, observational, noninterventional study. *Int J Chron Obstruct Pulmon Dis*. 2018 Feb 22;13:653-663. doi: 10.2147/COPD.S153969.
 8. Zhang P, Samartkit N, Masingboon K. Factors associated with health-related quality of life among employed individuals with chronic obstructive pulmonary disease: A correlational study in China. *Belitung Nurs J*. 2023 Jun 26;9(3):271-279. doi: 10.33546/bnj.2654.
 9. Меков Е, Боянов М. Нарушения в тиреоидната ос и хормони при хронична обструктивна белодробна болест . *Endokrinologîa*, 2022, Vol 27, Issue 2, p73 .
 10. Malakauskas K, Floreskul V, Štelemėkas M, Ivanauskienė R. Direct medical costs of newly diagnosed cases of chronic obstructive pulmonary disease in Lithuania. *Pulmonologija ir alergologija*, 2018; 2(2), 136-141. DOI: 10.37499/PIA.169.
58. Tachkov K., **G. Petrova**. Budget impact analysis of inhibitors hemophilia therapy with bypassing agents. *Journal of IMAB*. 2019; 25 (2): 2511-2515
- Цитирания:**
1. Georgieva S. Health technology assessment of biotechnology medicines with focus on hospital pharmacy. *International Journal of Biotech Trends and Technology (IJBTT)*, 2020; Volume 10 Issue 2; p:16-19. DOI:10.14445/22490183/IJBTT-V10I2P603.

2018

59. Manoela Manova, Alexandra Tzvetanova Savova, Mariya Andreeva Vasileva, Silvia , Maria Kamusheva, Daniela Grekova, Valentina Petkova, **Guenka Ivanova Petrova**. COMPARATIVE ANALYSIS OF PRICES OF BIOLOGICAL PRODUCTS FOR TREATMENT OF RHEUMATOID ARTHRITIS. *Front Pharmacol*. 2018; 9: 1070. Published online 2018 Sep 20. doi: 10.3389/fphar.2018.01070.

Цитирания:

1. V Lin YJ, Anzaghe M, Schülke S. Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. *Cells*. 2020 Apr 3;9(4):880. doi: 10.3390/cells9040880.
2. Sarzi-Puttini P, Ceribelli A, Marotto D, Batticciotto A, Atzeni F. Systemic rheumatic diseases: From biological agents to small molecules. *Autoimmun Rev*. 2019 Jun;18(6):583-592. doi: 10.1016/j.autrev.2018.12.009.
3. Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure. *Front Pharmacol*. 2021 Jun 25;12:625296. doi: 10.3389/fphar.2021.625296.
4. Greenblatt HK, Kim HA, Bettner LF, Deane KD. Preclinical rheumatoid arthritis and rheumatoid arthritis prevention. *Curr Opin Rheumatol*. 2020 May;32(3):289-296. doi: 10.1097/BOR.0000000000000708.
5. Simoens S, Vulto AG. A health economic guide to market access of biosimilars. *Expert Opin Biol Ther*. 2021 Jan;21(1):9-17. doi: 10.1080/14712598.2021.1849132.
6. Massalska M, Maslinski W, Ciechomska M. Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19. *Cells*. 2020 Aug 11;9(8):1876. doi: 10.3390/cells9081876.
7. Babaahmadi M, Tayebi B, Gholipour NM, Bendele P, Pheneger J, Kheimeh A, Kamali A, Molazem M, Baharvand H, Eslaminejad MB, Hajizadeh-Saffar E, Hassani SN. Long-term passages of human clonal mesenchymal stromal cells can alleviate the disease in the rat model of collagen-induced arthritis resembling early passages of different heterogeneous cells. *J Tissue Eng Regen Med*. 2022 Dec;16(12):1261-1275. doi: 10.1002/term.3368.
8. Janssen Daalen JM, den Ambtman A, Van Houdenhoven M, van den Bemt BJF. Determinants of drug prices: a systematic review of comparison studies. *BMJ Open*. 2021 Jul 15;11(7):e046917. doi: 10.1136/bmjopen-2020-046917.
9. Shuai Z, Zheng S, Wang K, Wang J, Leung PSC, Xu B. Reestablish immune tolerance in rheumatoid arthritis. *Front Immunol*. 2022 Sep 30;13:1012868. doi: 10.3389/fimmu.2022.1012868.
10. Batko B, Rolska-Wójcik P, Władysiuk M. Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment-A Systematic Literature Review. *Int J Environ Res Public Health*. 2019 Aug 17;16(16):2966. doi: 10.3390/ijerph16162966.

11. Vogler S, Salcher-Konrad M, Habimana K. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines? *Expert Rev Pharmacoecon Outcomes Res.* 2023 Jul-Dec;23(8):867-878. doi: 10.1080/14737167.2023.2237683.
12. Ghabri S, Binard A, Pers YM, Maunoury F, Caro JJ. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France. *Value Health.* 2020 Apr;23(4):461-470. doi: 10.1016/j.jval.2019.12.003.
13. Jurczak W, Długosz Danecka M, Buske C. Rituximab biosimilars for lymphoma in Europe. *Expert Opin Biol Ther.* 2019 Oct;19(10):1045-1056. doi: 10.1080/14712598.2019.1665017.
14. Millham LRI, Scott JA, Sax PE, Shebl FM, Reddy KP, Losina E, Walensky RP, Freedberg KA. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States. *J Acquir Immune Defic Syndr.* 2020 Feb 1;83(2):148-156. doi: 10.1097/QAI.0000000000002241.
15. Stiff KM, Cline A, Feldman SR. Tracking the price of existing biologics when drugs enter the market. *Expert Rev Pharmacoecon Outcomes Res.* 2019 Aug;19(4):375-377. doi: 10.1080/14737167.2019.1630274.
16. Maksabedian Hernandez EJ, Graf M, Portelli A, Shafrin J. Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators. *J Med Econ.* 2022 Jan-Dec;25(1):1118-1126. doi: 10.1080/13696998.2022.2113252.
17. Destiani DP, Naja S, Dewi S, Rahmadi AR, Sulaiman SAS, Abdulah R. Efficacy of methotrexate in reducing the risk of bone erosion in patients with rheumatoid arthritis: a systematic review of randomized controlled trials. *Osteoporos Int.* 2021 May;32(5):805-816. doi: 10.1007/s00198-020-05743-z.
18. Lee HJ, Han E, Kim H. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea. *Appl Health Econ Health Policy.* 2020 Aug;18(4):557-566. doi: 10.1007/s40258-019-00547-7.
19. Liu Y, Bo Z, Liu D, Diao S, Yang C, Li H, Zeng L, Yu Q, Zhang L. Trends and frontiers of research on pharmacoeconomics from 2012-2021: a scientometric analysis. *Ann Transl Med.* 2022 Mar;10(6):327. doi: 10.21037/atm-22-1050.

20. Nathalie LM, Mulligen VE, Maria WAEA, Wilhelmina HJM, Pieter JPH; tREACH group investigators. Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients. *Rheumatology (Oxford)*. 2021 Dec 1;60(12):5765-5774. doi: 10.1093/rheumatology/keab251. Erratum in: *Rheumatology (Oxford)*. 2022 Oct 6;61(10):4219.
21. Nookala Krishnamurthy M, Narula G, Gandhi K, Awase A, Pandit R, Raut S, Singh R, Gota V, Banavali SD. Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia. *JCO Glob Oncol*. 2020 Jul;6:1009-1016. doi: 10.1200/GO.20.00113.
22. Cross RK, Stewart AL, Edgerton CC, Shah B, Welz JA, Kay J. Implementation Strategies of Biosimilars in Healthcare Systems: The Path Forward. *American Health & Drug Benefits*, 2022; 15(2).p 45.
23. Al-Abdulkarim H, Sharma Y, Attar SM, Husain W, Al-Homood I, Al Omari B, Mohamed O, Alsaqa'aby M, Jaheen AM, Anwar A, Hamad TM, Alzahrani Z. Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia. *J Med Econ*. 2024 Jan-Dec;27(1):134-144. doi: 10.1080/13696998.2023.2299176.
24. Honne K, Bando M, Mieno MN, Iwamoto M, Minota S. Bronchiectasis is as crucial as interstitial lung disease in the severe pneumonia that occurs during treatment with biologic DMARDs in rheumatoid arthritis: a retrospective cohort study in a single facility. *Rheumatol Int*. 2022 Aug;42(8):1341-1346. doi: 10.1007/s00296-021-04934-z.
25. Yin Y, Liu M, Zhou E, Chang X, He M, Wang M, Wu J. Efficacy and safety of jakinibs in rheumatoid arthritis: a systematic review and meta-analysis. *Clin Rheumatol*. 2021 Oct;40(10):3989-4005. doi: 10.1007/s10067-021-05686-8.
26. Prabavathy K, Nalini M. Deep Learning Enabled Whale Optimization Algorithm for Accurate Prediction of RA Disease. *Salud, Ciencia y Tecnología-Serie de Conferencias*, 2024; 3, 652-652. DOI: 10.56294/sctconf2024652.
27. Njonnou SRS, Ouankou CN, Lekpa FK, Balti EV, Choukem SP. Availability of drugs for severe COVID-19 in sub-Saharan Africa. *Pan Afr Med J*. 2020 May 26;35(Suppl 2):48. doi: 10.11604/pamj.supp.2020.35.2.23698.
28. КАРАТЕЕВ ДЕ, Лучихина ЕЛ. Применение биоаналогов генно-инженерных биологических препаратов при ревматических заболеваниях. *Эффективная фармакотерапия*, 2018; (33), 54-62.

29. Song YW, Park YB, Kim J. LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis. *Expert Opin Biol Ther*. 2021 Jan;21(1):1-8. doi: 10.1080/14712598.2020.1701650.
 30. Cross R, Stewart A, Edgerton C, Shah B, Welz J, Kay J. Implementation Strategies of Biosimilars in Healthcare Systems: The Path Forward. *American Health and Drug benefits*, 2022; 15, 2, <https://www.ahdbonline.com/issues/2022/june-2022-vol-15-no-2/3222-implementation-strategies-of-biosimilars-in-healthcare-systems-the-path-forward>
 60. M. Kamusheva, M. Vasileva, A. Savova, M. Manova, **G. Petrova**. An overview of the reimbursement decision-making processes in Bulgaria as a reference country for the middle-income European countries. *Frontiers in Public Health*, 2018;6:61.
- Цитирания:**
1. Wei X. Practice of College Financial Online Reimbursement System Under the Background of Internet. *Cyber Security Intelligence and Analytics (CSIA 2021)*, Conference paper, pp 98-105.
 2. Цветкова А. Оценка на здравни технологии – от политики до пациента Приложение на здравните технологии при скрининг, терапия и профилактика на захарен диабет тип 2. Варна, 2020. ISBN 978-619-221-294-0.
61. Grekova, D.D., Andreevska, K.G., **Petrova, G.**, Petkova, V. Assessment of the social and economic burden of glaucoma in Bulgaria. *Biomedical Research (India)*, 2018; 29 (12): 2578-2581. DOI: 10.4066/biomedicalresearch.29-18-647

Цитирания:

1. Adda M, Amon S, Nonvignon J, Aikins M, Aryeetey GC. Economic cost of management of glaucoma in public and private health facilities in the Tema metropolis in Ghana. *Ghana Medical Journal*, 2024; 58(1), 17-25. DOI: 10.4314/gmj.v58i1.4.
2. Velkovski Z, Belevska M, Gjorgjeska B, Djordjevic-Jocic J. Cost effectiveness analysis associated to the treatment of primary open- angle glaucoma according to disease severity. *Serbian Archives of Medicine*, 2022; 150 (3-4). pp. 177-182. ISSN 2406-0895 DOI: 10.2298/SARH211219021V.
3. Velkovski Z, Belevska M, Dastevska EG. PHARMACOECONOMIC IMPLICATIONS GENERATED BY PRIMARY OPEN-ANGLE GLAUCOMA ON WORKERS. *Acta Medica Medianae*, 2021, Vol 60, Issue 3, p11. DOI 10.5633/amm.2021.0302.
4. Velkovski Z, Belevska M, Dastevska EG. ASSESSMENT OF THE SOCIAL BURDEN ON PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA. *Acta Medica Medianae*, 2021, Vol 60, Issue 4, p30. DOI 10.5633/amm.2021.0405.

62. Ignatova D, Onchev G, **Petrova G**, Kamusheva M. Burden of informal care for individuals with schizophrenia and affective disorders prior to hospital admission, The European Journal of Psychiatry, 2018, 12 (24): DOI: 10.1016/j.ejpsy.2018.11.002

Цитирания:

1. Dijkxhoorn MA, Padmakar A, Bunders JFG, Regeer BJ. Stigma, lost opportunities, and growth: Understanding experiences of caregivers of persons with mental illness in Tamil Nadu, India. Transcult Psychiatry. 2023 Apr;60(2):255-271. doi: 10.1177/13634615211059692.
2. Liu, YC. Caregiving experience associated with unpaid carers of persons with schizophrenia: a scoping review. Social Work in Mental Health, 2024; 22(2), 219-245. DOI: 10.1080/15332985.2023.2282932.
3. Eka AR; DAULIMA NHC , SUSANTI H. The Role of Informal Leaders in Restraint and Confining People with Mental Health Issues in Manggarai, Indonesia. European Journal of Mental Health, 2022, Vol 17, Issue 1, p25. DOI 10.5708/EJMH/17.2022.1.3.
4. Rindayati R, Yusuf A, Mundakir M, Nasir A, Illahiati NK. Psychological Burden Experiences and Coping Strategies of Family Who Have Family Members With Schizophrenia. Malaysian Journal of Medicine & Health Sciences, 2023, Vol 19, p23 .

2019

63. Ignatova D, Kamusheva M, **Petrova G**, Onchev G, Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria. Biotechnology & Biotechnological Equipment, 2019; 11(1): 1-10

Цитирания:

1. Sharma S, Sharma S, Patel N . Decoding the relationship of service operations enablers in healthcare industry. Journal of Operations and Strategic Planning, 2019; 2(2), 99-117. DOI: 10.1177/2516600X19889491.

64. Konstantin Tachkov, Konstantin Mitov, Maria Kamusheva, Miglena Doneva, **Guenka Ivanova Petrova**. Pilot study on the cost of some oncohematology diseases in Bulgaria. Front. Public Health | doi: 10.3389/fpubh.2019.00070

Цитирания:

1. Georgieva S. Health technology assessment of biotechnology medicines with focus on hospital pharmacy. International Journal of Biotech Trends and Technology (IJBTT), 2020; Volume 10 Issue 2; p:16-19. DOI:10.14445/22490183/IJBTT-V10I2P603.

65. Vassileva M, M Kamusheva, M Manova, A Savova, K Tachkov, **G Petrova**. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria. Expert Review of Pharmacoeconomics & Outcomes Research 2019; 11 (2) <https://doi.org/10.1080/14737167.2019.1592680>

Цитирания:

1. Dzhafer N, Papathanasiou JV. Compassionate Drug Use - Time Arising for a New Law in Bulgaria in the Era of COVID-19. *Folia Med (Plovdiv)*. 2020 Sep 30;62(3):592-596. doi: 10.3897/folmed.62.e53742.
 2. Цветкова А. Оценка на здравни технологии – от политики до пациента Приложение на здравните технологии при скрининг, терапия и профилактика на захарен диабет тип 2. Варна, 2020. ISBN 978-619-221-294-0.
 3. Georgieva S. Health technology assessment of biotechnology medicines with focus on hospital pharmacy. *International Journal of Biotech Trends and Technology (IJBT)*, 2020; Volume 10 Issue 2; p:16-19. DOI:10.14445/22490183/IJBT-V10I2P603.
 66. Kamusheva, M., Rusenova, Y., Vandeva, S., Elenkova, A., Zaharieva, S., Doneva, M., Mitkova, Z., **Petrova, G.** Economic and pharmaco-economic analysis of acromegaly treatment: a systematic review, *Biotechnology & Biotechnological Equipment*. 2019;33:1, 1560-1571, DOI: 10.1080/13102818.2019.1680317
- Цитирания:**
1. Voumik LC, Karthik R, Ramamoorthy A, Dutta A. A Study on Mathematics Modeling using Fuzzy Logic and Artificial Neural Network for Medical Decision Making System. In 2023 International Conference on Computational Intelligence and Sustainable Engineering Solutions (CISES) (pp. 492-498).
67. Dimitrova, D., Tachkov, K., **Petrova, G.** Economic consequences of the implementation of national screening program for chronic HCV infection, *Expert Review of Pharmacoeconomics & Outcomes Research*, 2019, DOI:10.1080/14737167.2019.1666000
- Цитирания:**
1. Carty PG, Fawsitt CG, Gillespie P, Harrington P, O'Neill M, Smith SM, Teljeur C, Ryan M. Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations. *Appl Health Econ Health Policy*. 2022 Mar;20(2):171-183. doi: 10.1007/s40258-021-00694-w.
 2. Georgieva S. Health technology assessment of biotechnology medicines with focus on hospital pharmacy. *International Journal of Biotech Trends and Technology (IJBT)*, 2020; Volume 10 Issue 2; p:16-19. DOI:10.14445/22490183/IJBT-V10I2P603.
68. Tachkov K., Mitov K., Mitkova Z., Kamusheva M., Dimitrova M., Petkova V., Savova A., Doneva M., Tcarukiev D., Valov V., Angelova G., Manova M., **Petrova G** Improved quality of diabetes control reduces complication costs in Bulgaria *Biotechnology & Biotechnological Equipment*, 2019, 33:1, 814-820, DOI: 10.1080/13102818.2019.1604160.

Цитирания:

1. Левтерова Б, Константинова М, Василева Е. СВЪРЗАНО СЪС ЗДРАВЕТО КАЧЕСТВО НА ЖИВОТ ПРИ ДЕЦА И ЮНОШИ СЪС ЗАХАРЕН ДИАБЕТ ТИП 1. *General Medicine / Obsta Medicina*, 2023, Vol 25, Issue 2, p19.

2. Tsvetkova A, Mihaylova S. SOCIAL AND ECONOMIC ASPECTS OF THE INCREASING INCIDENCE OF DIABETES IN VARNA AND BULGARIA. J of IMAB. 2021 Apr-Jun;27(2), pp 3978- 3984. DOI: 10.5272/jimab.2021273.3978.
 3. Цветкова А. Оценка на здравни технологии – от политики до пациента Приложение на здравните технологии при скрининг, терапия и профилактика на захарен диабет тип 2. Варна, 2020. ISBN 978-619-221-294-0.
 4. Georgieva S. Health technology assessment of biotechnology medicines with focus on hospital pharmacy. International Journal of Biotech Trends and Technology (IJBT), 2020; Volume 10 Issue 2; p:16-19. DOI:10.14445/22490183/IJBT-V10I2P603.
69. Grelewska J, Jakubczyk M, Niewada M, Lipka I, **Petrova G**, Tcharaktchiev D, Mitkova Z, Tsonev S, Verkauskiene R, Pejicic S, Vulic D, Seranic A, Pana A, Vasile Ileanu B, Bonča P, Janša K, Valov V, Jokubauskiene G, Hałdaś M, Jusufovic R, Ciocirlan R, Stariha J, Russel-Szymczyk M. The cost of macro- and microvascular diseases in patients with diabetes mellitus in selected Central and Eastern European countries. DOI:10.7365/JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH. 2019; 1:1-17
- Цитирания:**
1. Cardio-Metabolic Academy Europe East. Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel. Diabetes Res Clin Pract. 2021 Feb;172:108535. doi: 10.1016/j.diabres.2020.108535.
70. Mitkova, Z., Mitov, K., Valov, V., Manova, M., Savova, A., Kamusheva, M., Tcharaktchiev, D., Angelov, Z., Angelova, **Petrova, G**. Incretins and SGLT-2I therapy of type 2 diabetes – Real life study of their therapeutic and economic effects (2019) Frontiers in Pharmacology, 10 (MAR), art. no. 364, DOI: 10.3389/fphar.2019.00364
- Цитирания:**
1. Цветкова А. Оценка на здравни технологии – от политики до пациента Приложение на здравните технологии при скрининг, терапия и профилактика на захарен диабет тип 2. Варна, 2020. ISBN 978-619-221-294-0.
71. Tkachova O, Iakovlieva L, Mitkova Z, Manova M, Savova A, **Petrova G**. An affordability of statins therapy - comparative analysis between Ukraine and Bulgaria. BMC Health Services Research. 2019;19(1):902. Published 2019 Nov 27. doi:10.1186/s12913-019-4736-3
- Цитирания:**
1. Répásy B, Gazsó T, Elmer D, Pónusz-Kovács D, Kajos FL, Csákvári T, Kovács B, Boncz I. The long-term effect of generic price competition on the Hungarian statin market. BMC Health Serv Res. 2023 May 6;23(1):447. doi: 10.1186/s12913-023-09431-6.

2. Ковачка Г, Герасимов Н, Камушева М. ДОСТЪПНОСТ И РЕИМБУРСИРАНЕ НА ТЕРАПИЯТА С АНТИХИПЕРЛИПИДЕМИЧНИ ЛЕКАРСТВЕНИ ПРОДУКТИ В БЪЛГАРИЯ. Medical Review - Cardiovascular Diseases, 2020; Vol 51, Issue 2, p10, ISSN 0204-6865.

2020

72. Mitkova, Z., Vasileva, M., Savova, A., Manova, M., Terezova, S., **Petrova, G.** Comparison of Cardiovascular Medicines Prices in Four European Countries (2020) Frontiers in Public Health, 8, art. no. 433, DOI: 10.3389/fpubh.2020.00433

Цитирания:

1. Siegmeier F, Büssgen M. Indication-wide drug pricing: Insights from the pharma market. J Pharm Policy Pract. 2022 Aug 29;15(1):53. doi: 10.1186/s40545-022-00451-x.
2. Masiukovich N. Regulation of the pharmaceutical market in the Western Balkan countries . Health Policy, Economics and Sociology, 2023; 7(1).
73. Milushewa, P., Doneva, M., **Petrova, G.** Pharmacoeconomic studies of the asthma therapy (2020) General Medicine, 22 (1), pp. 57-66.
74. K. Tachkov, D. Ignatova, K. Mitov a, M. Kamushevaa, G. Petrova. Trends in the cost and utilization of psychotropic medicines for major psychiatric disorders in Bulgaria from 2013 to 2017. Eur. J. Psychiat. 2020;xxx(xx):xxx---xxx

Цитирания:

1. Kim J, Rim SJ, Jo M, Lee MG, Park S. The Trend of Psychiatric Visits and Psychiatric Medication Prescription Among People Tested for SARS-CoV-2 During the Initial Phase of COVID-19 Pandemic in South Korea. Psychiatry Investig. 2022 Jan;19(1):61-71. doi: 10.30773/pi.2021.0247.

2021

75. Seitaridou Y, Tsekov I, Kamusheva M, Dimitrova M, **Petrova G.** Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece. Expert Review of Pharmacoeconomics & Outcomes Research. 2021; 22(2):241-246. doi: 10.1080/14737167.2021.1981134.
76. Tachkov, K.; Mitkova, Z.; Boyadzieva, V.; **Petrova, G.** Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria. Pharmaceuticals 2021, 14, 64. <https://doi.org/10.3390/ph14010064>

Цитирания:

1. Car E, Vulto AG, Houdenhoven MV, Huys I, Simoens S. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Front Pharmacol. 2023 Apr 21;14:1151764. doi: 10.3389/fphar.2023.1151764.

2. Simoens S, Huys I. Emerging Insights into European Markets of Biologics, Including Biosimilars. Pharmaceuticals (Basel). 2022 May 17;15(5):615. doi: 10.3390/ph15050615.
 3. Vogler S, Panteli D, Zimmermann N, Busse R. Überblick über Maßnahmen zur Förderung des Einsatzes von Biosimilars in europäischen Ländern. In: Arzneiverordnungs-Report 2022. Aktuelle Daten, Kosten, Trends und Kommentare. Springer, Berlin, Heidelberg, pp. 57-81.
 4. Kobuszewski B. Biological medicinal products: reference and biosimilar products—selected issues. Journal of Education, Health and Sport, 2021; 11(10), 49-62. DOI: 10.12775/JEHS.2021.11.10.005 .
77. Mitkova, Z. **Petrova, G.** (2021) Analysis of the Household and HealthCare System Expenditures in Bulgaria. Frontiers in Public Health 9:675277. doi: 10.3389/fpubh.2021.675277
- Цитирания:**
1. Jakovljevic M, Pallegedara A, Vinayagathan T, Kumara AS. Editorial: Inequality in healthcare utilization and household spending in developing countries. Front Public Health. 2022 Aug 9;10:970819. doi: 10.3389/fpubh.2022.970819.
 2. Piekut M, Piekut K. Changes in Patterns of Consumer Spending in European Households. Sustainability (2071-1050), 2022, Vol 14, Issue 19, p12794. DOI 10.3390/su141912794.
78. Tachkov, K.; Mitkova, Z.; Milushewa, P.; **Petrova, G.** Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria. Healthcare 2021, 9, 697. <https://doi.org/10.3390/healthcare9060697>
- Цитирания:**
1. World Health Organization. Keeping the 100-year-old promise: making insulin access universal. Geneva; World Health Organization; 2021. | WHO IRIS | ID: who-348384 <https://pesquisa.bvsalud.org/portal/resource/pt/who-348384>
79. Mitkova, Z., **Petrova, G.** Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria (2021) Iranian Journal of Pharmaceutical Research, 20 (2), pp. 403-416. DOI: 10.22037/ijpr.2020.113660.14418
- Цитирания:**
1. Gonchar A, Sholoiko N. Impact of reimbursement program “Affordable Medicines” on consumption of beta-blockers in Ukraine in 2017-2020. Ukrainian Scientific Medical Youth Journal, 2022; Issue 3 (132), 13-18 DOI: 10.32345/USMJ.3(132).2022.13-18.
80. Tabor, B., Jakubczyk, M., Bojanic, L., Zawodnik, S., Bojkow, S., Chahoud, L., Sweeney, N., Benkovic, V., Christodoulou, C., Dimitrova, M., Liepina, E., Ondrušová, M., Pana, A., **Petrova, G.**, Petrovica, M., Ulici, A., Niewada, M. The economic burden of advanced

breast cancer (2021) Journal of Health Policy and Outcomes Research, 2021 (2), pp. 42-65. DOI: 10.7365/JHPOR.2021.2.6

81. Kostova, D., Stoev, S., Tachkov, K., **Petrova, G.** Cost-effectiveness of in vitro fertilization and controlled ovarian hyperstimulation before and after the COVID-19 outbreak (2021) Biotechnology and Biotechnological Equipment, 35 (1), pp. 1821-1827. DOI: 10.1080/13102818.2021.2022993

Цитирания:

1. Van Muylder A, D'Hooghe T, Luyten J. Economic Evaluation of Medically Assisted Reproduction: A Methodological Systematic Review. Med Decis Making. 2023 Oct-Nov;43(7-8):973-991. doi: 10.1177/0272989X231188129.
82. Godman, B., Hill, A., Simoens, S., Selke, G., Selke Krulichová, I., Zampirolli Dias, C., Martin, A.P., Oortwijn, W., Timoney, A., Gustafsson, L.L., Voncina, L., Kwon, H.-Y., Gulbinovic, J., Gotham, D., Wale, J., Cristina Da Silva, W., Bochenek, T., Allocati, E., Kurdi, A., Ogunleye, O.O., Meyer, J.C., Hoxha, I., Malaj, A., Hierländer, C., Sauermann, R., Hamelinck, W., **Petrova, G.**, Laius, O., Langner, I., Yfantopoulos, J., Joppi, R., Jakupi, A., Greiciute-Kuprijanov, I., Vella Bonanno, P., Piepenbrink, J., de Valk, V., Wladysiuk, M., Marković-Peković, V., Mardare, I., Fürst, J., Tomek, D., Obach Cortadellas, M., Zara, C., Pontes, C., McTaggart, S., Laba, T.-L., Melien, Ø., Wong-Rieger, D., Bae, S., Hill, R. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021) Expert Review of Pharmacoeconomics and Outcomes Research, 21 (4), pp. 527-540. DOI: 10.1080/14737167.2021.1884546

Цитирания:

1. Janez A, Battelino T, Klupa T, Kocsis G, Kuricová M, Lalić N, Stoian AP, Prázný M, Rahelić D, Šoupal J, Tankova T, Zelinska N. Hybrid Closed-Loop Systems for the Treatment of Type 1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe. Diabetes Ther. 2021 Dec;12(12):3107-3135. doi: 10.1007/s13300-021-01160-5.
2. Li L, Yang S, Chen Y, Tian L, He Y, Wu B, Dong D. Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis. Front Pharmacol. 2022 Jun 1;13:891008. doi: 10.3389/fphar.2022.891008.
3. Zhang Y, Wei Y, Li H, Chen Y, Guo Y, Han S, Shi L, Guan X. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China. Pharmacoeconomics. 2022 Jul;40(7):715-724. doi: 10.1007/s40273-022-01161-7.
4. Fontrier AM. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and

funding recommendations. *Soc Sci Med*. 2022 Aug;306:115119. doi: 10.1016/j.socscimed.2022.115119.

5. Mohammadpour S, Soleimanpour S, Javan-Noughabi J, Gallehzan NA, Aboutorabi A, Jahangiri R, Bagherzadeh R, Gorman JF, Nemati A. A systematic literature review on indirect costs of women with breast cancer. *Cost Eff Resour Alloc*. 2022 Dec 12;20(1):68. doi: 10.1186/s12962-022-00408-6.
6. Callenbach MHE, Ádám L, Vreman RA, Németh B, Kaló Z, Goettsch WG. Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook. *Drug Discov Today*. 2023 Jan;28(1):103433. doi: 10.1016/j.drudis.2022.103433.
7. Hofmarcher T, Szilagyi P, Gustafsson A, Dolezal T, Rutkowski P, Baxter C, Karamousouli E. Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit. *ESMO Open*. 2023 Aug;8(4):101593. doi: 10.1016/j.esmoop.2023.101593.
8. Wu Q, Lian Z, Wang X, Cheng H, Sun J, Yu H, Zhang G, Wu F, Liu J, Chen C. Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China. *Front Pharmacol*. 2023 Jan 12;13:1044798. doi: 10.3389/fphar.2022.1044798.
9. Németh B, Csanádi M, Inotai A, Ameyaw D, Kaló Z. Access to High-Priced Medicines in Lower-Income Countries in the WHO European Region [Internet]. Copenhagen Ø, Denmark: World Health Organization; 2022. PMID: 36542735.
10. Negoita SI, Ionescu RV, Zlati ML, Antohi VM, Nechifor A. New Regional Dynamic Cancer Model across the European Union. *Cancers (Basel)*. 2023 Apr 28;15(9):2545. doi: 10.3390/cancers15092545.
11. Zheng Z, Song X, Qiu G, Xu S, Cai H. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China. *Curr Med Res Opin*. 2023 Mar;39(3):433-440. doi: 10.1080/03007995.2023.2178081.
12. Ludwig WD, Mühlbauer B. Arzneiverordnungen 2021 im Überblick. In *Arzneiverordnungs-Report 2022* (pp. 3-27). Berlin, Heidelberg: Springer Berlin Heidelberg.
13. Chen R, Zhang Y, Lin K, Huang D, You M, Lai Y, Wang J, Hu Y, Li N. Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine

Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers. *Front Pharmacol.* 2022 Jul 22;13:871262. doi: 10.3389/fphar.2022.871262.

14. Wettstein DJ, Boes S. How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence. *Health Policy.* 2022 Feb;126(2):112-121. doi: 10.1016/j.healthpol.2021.12.007.
15. Heine RJSD, Thielen FW, Mathijssen RHJ, van Leeuwen RWF, Franken MG, Uyl-de Groot CA. Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab. *PLoS One.* 2024 Feb 1;19(2):e0293264. doi: 10.1371/journal.pone.0293264.
16. Lu T, Huang Y, Cai Z, Lin W, Chen X, Chen R, Hu Y. The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer. *Front Pharmacol.* 2023 Jul 26;14:1171302. doi: 10.3389/fphar.2023.1171302.
17. Rodriguez R, Brunner R, Spencer S, Qato DM. Time to inclusion in clinical guidance documents for non-oncological orphan drugs and biologics with expedited FDA designations: a retrospective survival analysis. *BMJ Open.* 2021 Dec 25;11(12):e057744. doi: 10.1136/bmjopen-2021-057744.
18. Ferreccio C. How Did We Get Here: The Best Vaccines Ever Facing the Highest Public Hesitancy? *Vaccines (Basel).* 2023 Aug 4;11(8):1323. doi: 10.3390/vaccines11081323.
19. Pham C, Niu F, Delate T, Buchschacher GL Jr, Li Y, Ekinci E, Le K, Hui RL. Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer. *BioDrugs.* 2023 Nov;37(6):891-899. doi: 10.1007/s40259-023-00624-3.
20. Girardin FR, Cohen K, Schwenkglenks M, Durand-Zaleski I. Editorial: Pharmacoeconomics in the era of health technology assessment and outcomes research to prioritize resource use, innovation and investment. *Front Pharmacol.* 2023 May 16;14:1210002. doi: 10.3389/fphar.2023.1210002.
21. Ghinea N, Lipworth W, Kerridge I, Zalcborg JR. How therapeutic advances have transformed the medical landscape: a primer for clinicians. *Intern Med J.* 2023 Aug;53(8):1306-1310. doi: 10.1111/imj.16142.
22. Ladner J, Madi F, Jayasundera R, Saba J, Audureau E. Phone contacts and treatment discontinuation predict survival cancer patients in a subsidized

- drug access program. *J Comp Eff Res*. 2023 Jul;12(7):e220210. doi: 10.57264/cer-2022-0210.
23. Tubić B, Jungić S. Regulatory aspects of biological medicines in Bosnia and Herzegovina. *Bosn J Basic Med Sci*. 2022 Jul 29;22(4):511-522. doi: 10.17305/bjbms.2021.6910.
 24. Capri S, Antoñanzas F, Levaggi R. The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach. *Expert Rev Pharmacoecon Outcomes Res*. 2023 Apr;23(4):431-438. doi: 10.1080/14737167.2023.2184801.
 25. Rahim UA, Roos NAC, Mustapa M, Nurdin A, Taridi NM, Yusof YAM. Anticancer Effects of Gingerol, Shogaol and Curcumin in Cervical Cancer: A Systematic Review Protocol. *Advances in Human Biology*. 2023; 13(3):p 246-251 | DOI: 10.4103/aihb.aihb_222_22.
 26. Jenei K, Meyers DE. Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations. *BMJ Open*. 2023 Oct 16;13(10):e066378. doi: 10.1136/bmjopen-2022-066378.
 27. van der Schans S, De Loos F, Boersma C, Postma MJ, Büller H. A novel perspective on pharmaceutical R&D costs: opportunities for reductions. *Expert Rev Pharmacoecon Outcomes Res*. 2022 Mar;22(2):167-175. doi: 10.1080/14737167.2022.1987219.
 28. Graili P. Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis. *Appl Health Econ Health Policy*. 2023 Jul;21(4):673-681. doi: 10.1007/s40258-022-00781-6.
 29. Liu X, Lang Y, Chai Q, Lin Y, Liao Y, Zhu Y. Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis. *Front Pharmacol*. 2022 Aug 22;13:872196. doi: 10.3389/fphar.2022.872196.
 30. Beletsi A, Stefanou G, Kourlaba G. Time From Marketing Authorization to Reimbursement of Medicines in Greece After the Introduction of the Health Technology Assessment Process From July 2018 to April 2022. *Value Health Reg Issues*. 2023 Jul;36:58-65. doi: 10.1016/j.vhri.2023.03.001.
 31. Alsagoor TM. The Impact of Drug Pricing and Insurance Coverage on Medication Adherence in Saudi. *American Journal of Financial Technology and Innovation*, 2023; 1(1), 24-34. DOI: 10.54536/ajfti.v1i1.2033
 83. Kamusheva M, Turcu-Stiolica A, Gierczynski J, Subtirelu M-S, Czech M ´ and Petrova G. Do Advanced Therapies Have a Future in the Lowand Middle-Income

Countries - The Case of Bulgaria, Romania, and Poland. *Front. Public Health*, 2021: 9:729847. doi: 10.3389/fpubh.2021.729847

Цитирания:

1. Gagelman N., et al. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. *The Lancet Haematology*, 2022, 9.10: e786-e795.
 2. Drummond M., Ciani O., Fornaro G., Jommi C., Dietrich, E. S., Espin, J., et al. How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?. *BMC health services research*, 2023: 23(1), 484.
 3. Sachetti, C. G., Júnior, A. B., de Carvalho, A. C. C., Araujo, D. V., & da Silva, E. N. Challenges and opportunities for access to Advanced Therapy Medicinal Products in Brazil. *Cytotherapy*. 2024
 4. Kostadinov, Kostadin, et al. "Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape." *Healthcare*. 2024; 12 (4)
 5. Karahan, E. B., & Kockaya, G. Gene and Cell Therapies Overview Under the Light of Health Economics. *Health Economics and Management Review*, 2022; 3(4): 15-22.
84. Tachkov, K., Boydzhieva, V., Mitkova, Z., Stoilov, N., **Petrova, G.** PHARMACOECONOMIC MODELS IN RHEUMATOLOGY (2021) *Rheumatology (Bulgaria)*, 29 (4), pp. 15-39. DOI: 10.35465/29.4.2021
85. Godman B., Haque M., Leong T., Allocati E., Kumar S., Islam S., Charan J., Akter F., Kurdi A., Vassalo C., Bakar M., Rahim S., Sultana N., Deebea F., Khan M., Muksudul A. B. M., Jahan I., Kamal Z., Hasin H., Murshid M., Nahar S., Haque M., Dutta S., Abhayanand J., Kaur R., Rwegerera G., Macedo do Nascimento R., Godói I., Irfan M., Amu A., Matowa P., Acolatse J., Incoom R., Sefah I., Acharya J., Opanga S., Njeri L., Kimonge D., Kwon H-Y., Bae S., Khuan K., Abubakar A., Sani I., Khan T., Hussain S., Saleem Z., Malande O., Piloya-Were T., Gambogi R., Ortiz C., Alutuli L., Kalungia A., Hoxha I., Markovic-Pekovic V., Tubic B., Petrova G., Tachkov K., Laius O., Harsanyi A., Inotai A., Jakupi A., Henkuzens S., Garuoliene K., Gulbinovic J., Wladysiuk M., Rutkowski J., Mardare I., Fürst J., McTaggart S, MacBride-Stewart S., Pontes C., Zara C., Tagoe E., Banzi R., Wale J. and Jakovljevic M.. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. *Front. Public Health*, Sec. Health Economics, 2021; 9, <https://doi.org/10.3389/fpubh.2021.671961>

Цитирания:

1. HAJI, Mona; KERBACHE, Laoucine; AL-ANSARI, Tareq. Evaluating the performance of a safe insulin supply chain using the AHP-TOPSIS approach. *Processes*, 2022, 10.11: 2203.

2. Hu, W., Zhai, C., Sun, H., Gong, X., Cui, L., Cai, L., ... & Zou, Y. (2023). The global burden of disease attributable to metabolic risks in 204 countries and territories from 1990 to 2019. *Diabetes Research and Clinical Practice*, 196, 110260.
3. Heinemann, L., Davies, M., Home, P., Forst, T., Vilsbøll, T., & Schnell, O. (2023). Understanding biosimilar insulins-development, manufacturing, and clinical trials. *Journal of diabetes science and technology*, 17(6), 1649-1661.
4. AlRuthia, Y., Bahari, O. H., Alghnam, S., Alrumaih, A. M., Asiri, H., Alshammari, M., ... & Al-Abdulkarim, H. A. (2022). Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia. *Frontiers in Public Health*, 10, 852721.
5. Wang, Y., Zhou, Y., Ding, J., Li, X., Guo, F., Zhang, J., & Ding, L. (2022). Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints. *Frontiers in Pharmacology*, 13, 962201.
6. Afshari, S., Ameri, H., Baharinya, S., Arab-Zozani, M., & Mojahedian, M. M. (2022). Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. *Expert Review of Pharmacoeconomics & Outcomes Research*, 22(2), 351-364.
7. Yang, J., Zhao, X., Li, J., Zhang, K., Zhang, Z., Chang, S., ... & Shao, Y. (2022). Creating China's biosimilar drugs regulatory system: a calculated approach. *Frontiers in Pharmacology*, 13, 815074.
8. Peng, K., Blais, J. E., Pratt, N. L., Guo, J. J., Hillen, J. B., Stanford, T., ... & Li, X. (2023). Impact of introducing infliximab biosimilars on total infliximab consumption and originator infliximab prices in eight regions: an interrupted time-series analysis. *BioDrugs*, 37(3), 409-420.
9. Talukder, S. H., Islam, T., Salahin, K. F., Akter, S., Farhana, D., Sultana, U. F., ... & Kurdi, A. (2022). COVID-19 and Health System Response for Management of Diabetes in Bangladesh: A national qualitative study of patients with diabetes and key healthcare professionals/policy makers. *medRxiv*, 2022-12.
10. Ji, L., Lu, Y., Li, Q., Fu, L., Luo, Y., Lei, T., ... & Meinicke, T. (2023). Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double-blind, placebo-controlled, parallel study. *Diabetes, Obesity and Metabolism*, 25(7), 1839-1848.
11. Rahalkar, H., Sheppard, A., & Salek, S. (2022). Biosimilar development and review process in the BRICS-TM countries: Proposal for a standardized model to

improve regulatory performance. *Expert Review of Clinical Pharmacology*, 15(2), 215-236.

12. Елсукова, О. С. (2023). ИСПОЛЬЗОВАНИЕ РЕКОМЕНДАЦИЙ CARE ДЛЯ ОПИСАНИЯ СЛУЧАЕВ ИЗ ПРАКТИКИ ВРАЧА. *РМЖ*, (2), 16-24.

13. Dogui, S., Htira, Y., Jemai, C., Aloui, K., & Echater, W. (2022). Audit of glycemic control of diabetic patients on insulin analogues: about 2915 insured persons of the CNAM (Tunisia). *La Tunisie Medicale*, 100(6), 438-444.

14. Rahalkar, H. Evaluation of the Regulatory Requirements for Development and Approval of Biosimilar Medicines in the BRICS-TM Countries: Improving Patients' Access. 2021

15. Вербовой, А. Ф., Долгих, Ю. А., & Шаронова, Л. А. (2021). Биосимиляры инсулинов в клинической практике. *Медицинский совет*, (21-1), 131-138.

16. Danne, T., Heinemann, L., & Bolinder, J. (2022). New insulins, biosimilars, and insulin therapy. *Diabetes Technology & Therapeutics*, 24(S1), S-35.

17. Danne, T., Heinemann, L., & Pieber, T. R. (2023). New Insulins, Biosimilars, and Insulin Therapy. *Diabetes Technology & Therapeutics*, 25(S1), S-44.

18. World Health Organization. (2021). Keeping the 100-year-old promise: making insulin access universal. In *Keeping the 100-year-old promise: making insulin access universal*.

19. Htira, Y., Jemai, C., Aloui, K., Gandoura, A. S., Echater, W., & Mami, F. B. (2022). Audit of glycemic control of diabetic patients on insulin analogues: about 2915 insured persons of the CNAM (Tunisia).

86. Daubner-Bendes R, Kovács S, Niewada M, Huic M, Drummond M, Ciani O, Blankart CR, Mandrik O, Torbica A, Yfantopoulos J, **Petrova G**, Holownia-Voloskova M, Taylor RS, Al M, Piniashko O, Lorenzovici L, Tarricone R, Zemplényi A and Kaló Z. Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. *Front. Public Health* (Section health economics) 2021;8:612410. doi: 10.3389/fpubh.2020.612410

Цитирования

1. Ming, J., He, Y., Yang, Y., Hu, M., Zhao, X., Liu, J., ... & Chen, Y. (2022). Health technology assessment of medical devices: current landscape, challenges, and a way forward. *Cost Effectiveness and Resource Allocation*, 20(1), 54.

2. Kirwin, E., Round, J., Bond, K., & McCabe, C. (2022). A conceptual framework for life-cycle health technology assessment. *Value in Health*, 25(7), 1116-1123.

3. Farah, L., Borget, I., Martelli, N., & Vallee, A. (2024). Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review. *Journal of Medical Internet Research*, 26, e51514.
4. Beall, R. F., Glazer, T., Ahmad, H., Buell, M., Hahn, S., Houston, A. R., ... & Kaplan, W. (2022). Patent “Evergreening” of Medicine–Device Combination Products: A Global Perspective. *Healthcare Policy*, 18(2), 14.
5. Vogler, S., & Windisch, F. (2022). Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections–Overview of Policies Applied in 17 European Countries. *Antibiotics*, 11(8), 987.
6. Yang, Y., & Yin, Z. (2023). Resilience of a Supply Chain-Based Economic Evaluation of Medical Devices From an Industry Perspective. *International Journal of Data Warehousing and Mining (IJDWM)*, 19(5), 1-18.
7. Arkova, E. S., Kuznetsova, Y. A., & Krasnova, L. S. (2022). LITERATURE REVIEW OF GUIDELINES FOR MEDICAL DEVICES ASSESSMENT. *Problems of Social Hygiene, Public Health and History of Medicine*, 30(s1), 966-971.
8. Арькова, Е. С., Кузнецова, Ю. А., & Краснова, Л. С. (2022). ЛИТЕРАТУРНЫЙ ОБЗОР РЕКОМЕНДАЦИЙ ДЛЯ ПРОВЕДЕНИЯ ОЦЕНКИ МЕДИЦИНСКИХ ИЗДЕЛИЙ. Проблемы социальной гигиены, здравоохранения и истории медицины, 30(S), 966-971.
9. Chavarina, K., Bayani, D., & Kairu, A. Concept Note for HTA guideline Project (A stepwise guide for HTA guideline development).
10. Rognoni, C., Barcellona, M. R., Bargellini, I., Bavetta, M. G., Bellò, M., Brunetto, M., ... & Tarricone, R. (2022). Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma. *Frontiers in Oncology*, 12, 920073.

2022

87. Tachkov K, Boyadzhieva V, Manev I, Stoilov N, Mitkova Z, Mitov K, **Petrova G** (2022) Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national level, *Biotechnology & Biotechnological Equipment*, 36:1, 828-837, DOI: 10.1080/13102818.2022.2131468
88. Mitkova, Z., Dimitrova, M., Doneva, M., Tachkov, K., Kamusheva, M., Marinov, L., Gerasimov, N., Tcharaktchiev, D., **Petrova, G.** Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria (2022) *Frontiers in Public Health*, 10, art. no. 1011928, DOI: 10.3389/fpubh.2022.1011928

89. Mitkova, Z., Doneva, M., Gerasimov, N., Tachkov, K., Dimitrova, M., Kamusheva, M., **Petrova, G.** Analysis of Healthcare Expenditures in Bulgaria (2022) Healthcare (Switzerland), 10 (2), art. no. 274, DOI: 10.3390/healthcare10020274

Цитирания:

1. Jakovljevic M, Pallegedara A, Vinayagathan T, Kumara AS. Editorial: Inequality in healthcare utilization and household spending in developing countries. Front Public Health. 2022 Aug 9;10:970819. doi: 10.3389/fpubh.2022.970819.
 2. Nedelcheva Y, Filipova M. Health culture study of pharmaceutical consumers in the environment of COVID-19. Bulgarian Journal of Public Health, 2022; 14(3). P.32 .
 3. Shivarov V, Grigorova D, Yordanov A. Relative Risk of Death in Bulgarian Cancer Patients during the Initial Waves of the COVID-19 Pandemic. Healthcare (Basel). 2023 Sep 20;11(18):2594. doi: 10.3390/healthcare11182594.
90. Tachkov, K., Zemlenyi, A., Kamusheva, M., Dimitrova, M., Siirtola, P., Pontén, J., Nemeth, B., Kalo, Z., **Petrova, G.** Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries (2022) Frontiers in Public Health, 10, art. no. 921226, DOI: 10.3389/fpubh.2022.921226

Цитирания:

1. Al Kuwaiti A, Nazer K, Al-Reedy A, Al-Shehri S, Al-Muhanna A, Subbarayalu AV, Al Muhanna D, Al-Muhanna FA. A Review of the Role of Artificial Intelligence in Healthcare. J Pers Med. 2023 Jun 5;13(6):951. doi: 10.3390/jpm13060951.
2. Nedbal C, Cerrato C, Jahrreiss V, Castellani D, Pietropaolo A, Galosi AB, Somani BK. The role of 'artificial intelligence, machine learning, virtual reality, and radiomics' in PCNL: a review of publication trends over the last 30 years. Ther Adv Urol. 2023 Sep 8;15:17562872231196676. doi: 10.1177/17562872231196676.
3. O'Reilly D, McGrath J, Martin-Loeches I. Optimizing artificial intelligence in sepsis management: Opportunities in the present and looking closely to the future. J Intensive Med. 2023 Nov 29;4(1):34-45. doi: 10.1016/j.jointm.2023.10.001.
4. Liang D, Cai X, Guan Q, Ou Y, Zheng X, Lin X. Burden of type 1 and type 2 diabetes and high fasting plasma glucose in Europe, 1990-2019: a comprehensive analysis from the global burden of disease study 2019. Front Endocrinol (Lausanne). 2023 Dec 13;14:1307432. doi: 10.3389/fendo.2023.1307432.
5. Adeoye J, Su YX. Leveraging artificial intelligence for perioperative cancer risk assessment of oral potentially malignant disorders. Int J Surg. 2024 Mar 1;110(3):1677-1686. doi: 10.1097/JS9.0000000000000979.

6. Salehinejad H, Meehan AM, Rahman PA, Core MA, Borah BJ, Caraballo PJ. Novel machine learning model to improve performance of an early warning system in hospitalized patients: a retrospective multisite cross-validation study. *EClinicalMedicine*. 2023 Nov 16;66:102312. doi: 10.1016/j.eclinm.2023.102312.
7. Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. *Heliyon*. 2024 Feb 15;10(4):e26297. doi: 10.1016/j.heliyon.2024.e26297.
8. Nilsen P, Svedberg P, Neher M, Nair M, Larsson I, Petersson L, Nygren J. A Framework to Guide Implementation of AI in Health Care: Protocol for a Cocreation Research Project. *JMIR Res Protoc*. 2023 Nov 8;12:e50216. doi: 10.2196/50216.
9. Mészáros Á, Kovács S, Héja T, Bagyura Z, Zemlényi A. Mapping Hungarian procedure codes to SNOMED CT. *BMC Med Res Methodol*. 2023 Oct 18;23(1):240. doi: 10.1186/s12874-023-02036-x.
10. Kaminski A, Gramelsberger G, Scheer D. Modeling for policy and technology assessment: Challenges from computerbased simulations and artificial intelligence. *TATuP-Zeitschrift für Technikfolgenabschätzung in Theorie und Praxis*, 2023; 32(1), 11-17.
11. Yadav R. Artificial Intelligence for Mental Health: A Double-Edged Sword. *Science Insights*, 2023; 43(5), 1115-1117. DOI:10.15354/si.23.co13.
91. Kirilova-Doneva, M., Kamusheva, M., Gerasimov, N., **Petrova, G.** Cost-Utility Analysis of Open Hernia Operations in Bulgaria. *Acta Medica Bulgarica*, 2022, 49(2), pp. 22–27
92. Pisana A., Wettermark B., Kurdi A., Tubic B., Pontes C., Zara C., Van Ganse E., **Petrova G.**, Mardare I., Fürst J., Roig-Izquierdo M., Melien O., Vella Bonanno P., Banzi R., Marković-Peković V., Mitkova Z., Godman G.. Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries *Front. Pharmacol.*, 2022; (13) Sec. Drugs Outcomes Research and Policies <https://doi.org/10.3389/fphar.2022.873556>

Цитирования:

1. Callenbach MHE, Ádám L, Vreman RA, Németh B, Kaló Z, Goettsch WG. Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook. *Drug Discov Today*. 2023 Jan;28(1):103433. doi: 10.1016/j.drudis.2022.103433.
2. Orlu GU, Abdullah RB. Zaremohzzabieh Z. Jusoh YY. Asadi S. Qasem YA. Haizan Nor RN. Mohd Nasir WMHB. A systematic review of literature on

sustaining decision-making in healthcare organizations amid imperfect information in the Big Data era. *Sustainability*, 2023; 15(21), 15476. DOI: 10.3390/su152115476.

3. Ispán F, Hegedüs T, Csanádi M, Nagy B. Goals and methods of managed entry agreements—can we get what we want?. *Health Policy and Technology*, 2023; 12(2), 100745. DOI: 10.1016/j.hlpt.2023.100745.
4. Pan M, Hu S, Zhang J, Xiang C, Babar ZU, Yang C. Procurement of medicines to treat cancer, 2015-2020, China. *Bull World Health Organ*. 2022 Dec 1;100(12):758-768. doi: 10.2471/BLT.22.288420.
5. Elkaddoum R, Zakhour J, Hajal M, Aoun M, Njeim M, Mahrous M, Al-Shamsi HO, Brahim ZB, Khatib SA, Kourie HR. Improving the management of ALK-rearranged non-small-cell lung cancer through a mobile application: a physicians-based survey. *Pharmacogenomics*. 2023 Aug;24(13):725-730. doi: 10.2217/pgs-2023-0111.
6. Capri S, Antoñanzas F, Levaggi R. The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach. *Expert Rev Pharmacoecon Outcomes Res*. 2023 Apr;23(4):431-438. doi: 10.1080/14737167.2023.2184801.

93. Mitkova Z., Dimitrova M., Mitkov J., **Petrova G.** Impact of COVID-19 pandemic on outpatient depression treatment and NHIF expenditure. *Journal of Applied Pharmaceutical Science*, 2021; 12(05): 142-148, DOI: 10.7324/JAPS.2022.120511

2023

94. Manova M, Mitkova ZE, Savova A, Borisova A, Peikova L, Mitkov J, **Petrova G.** Impact of generics competition on prices and utilization of antiepileptic medicines in Bulgaria. *Journal of Applied Pharmaceutical Science*, 2023. <https://doi.org/10.7324/JAPS.2023.115004>
95. Tachkov, K., Savova, A., Manova, M., **Petrova, G.** Tackling reimbursement challenges to fair access to medicines—introduction to the topic (2023) *Expert Review of Pharmacoeconomics and Outcomes Research*, 23 (6), pp. 597-606. DOI: 10.1080/14737167.2023.2203384
96. Zemlényi, A., Tachkov, K., Balkanyi, L., Németh, B., Petykó, Z.I., **Petrova, G.**, Czech, M., Dawoud, D., Goettsch, W., Gutierrez Ibarluzea, I., Hren, R., Knies, S., Lorenzovici, L., Maravic, Z., Piniashko, O., Savova, A., Manova, M., Tesar, T., Zerovnik, S., Kaló, Z. Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment (2023) *Frontiers in Public Health*, 11, art. no. 1088121, DOI: 10.3389/fpubh.2023.1088121

Цитирания:

1. Li LT, Haley LC, Boyd AK, Bernstam EV. Technical/Algorithm, Stakeholder, and Society (TASS) barriers to the application of artificial intelligence in

medicine: A systematic review. J Biomed Inform. 2023 Nov;147:104531. doi: 10.1016/j.jbi.2023.104531.

2. Bente BE, Van Dongen A, Verdaasdonk R, van Gemert-Pijnen L. eHealth implementation in Europe: a scoping review on legal, ethical, financial, and technological aspects. *Frontiers in Digital Health*, 2024; Vol 6, 1332707. DOI: 10.3389/fdgth.2024.1332707.
 3. Elmaoğlu E, Coşkun AB, Yüzer Alsaç S. Digital Transformation: The Role, Potential, and Limitations of ChatGPT in Child Health Education. *American Journal of Health Education*, 2024 55(1), 69–72. DOI: 10.1080/19325037.2023.2277937.
 4. Choudhary S, Khatoon N, Singh KR, Divya K, Kumar S D, Gupta AK. An Evaluation of AI-Driven Data Mining Techniques for Large-Scale Data Processing. In 2023 3rd International Conference on Smart Generation Computing, Communication and Networking (SMART GENCON)2023; (pp. 1-7). IEEE. DOI: 10.1109/SMARTGENCON60755.2023.10441964.
97. Tachkov K., Nikolova P., Vitanska-Simeonova R., Boyadzhieva V., Stoilov N., **Petrova G.** Cost-effectiveness of therapeutic drug monitoring (TDM) of biologic treatment in rheumatic diseases: a narrative review, *Biotechnology & Biotechnological Equipment*, 2023, 37, 1, <https://doi.org/10.1080/13102818.2023.2250469>
- Цитирания:**
1. Gavan SP, Payne K, Barton A. Overcoming provider barriers to therapeutic drug monitoring of tumour necrosis factor inhibitors for rheumatoid arthritis: a qualitative analysis. *Rheumatol Adv Pract*. 2024 Mar 4;8(2):rkae030. doi: 10.1093/rap/rkae030.
98. Mitkova Z., Manev I., Tachkov K., Boyadzhieva V., Stoilov N., Doneva M., **Petrova G.** How Managed Entry Agreements Influence the Patients Affordability to Biological Medicines—Bulgarian Example. *Healthcare* 2023; 11: 2427. <https://doi.org/10.3390/healthcare11172427>
99. Savova A., Manova M., Tachkov K., **Petrova G.** The role of insurance policies in the drug pricing landscape, *Expert Review of Pharmacoeconomics & Outcomes Research*, 2023; DOI: 10.1080/14737167.2023.2292693
100. Dimitrova M., Seitaridou Y., Lazarova E., **Petrova G.**, Mitov K., Milanov I., Marinov L., Kamusheva M., Panayotov P. Cost-effectiveness of disease-modifying treatments for multiple sclerosis in Bulgaria based on evidence from real world settings. *Farmacia*, 2023, Vol. 71, 6: 1324-1331, <https://doi.org/10.31925/farmacia.2023.6.24>
101. Dimitrova M., Dimitrov R., Ahchiyska K., Nikolaeva M., Ganova M., **Petrova G.** Digital health in Bulgaria: Imagination or possible reality? *Pharmacia* 2023; 70(3): 649–655 DOI 10.3897/pharmacia.70.e108957

102. Karanyotova S, Topova B, Petrova E, Doychev P, Kapitanska E, **Petrova G**, Mitkova Z and Dimitrova M (2023) Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria. *Front. Public Health* 11:1073733. doi: 10.3389/fpubh.2023.1073733

2024

103. Dadanbekova D., Zhakipbekov D., Kodasbayev A., Datkhayev A., **Petrova G.**, Tachkov K. Cost-effectiveness of cardiomyopathy ambulatory care with sacubitril/valsartan vs standard therapy after COVID-19 in Kazakhstan. *Pharmacia* 70(3): 649–655 DOI 10.3897/pharmacia.70.e108957
104. Jakubowski S, Kawalec P, Holko P, Kowalska-Bobko I, Kamusheva M, **Petrova G**, Draganić P, Fuksa L, Männik A, Ispán F, Briedis V, Bianchi I, Paveliu MS and Tesar T (2024), Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries. *Front. Pharmacol.* 15:1369178. doi: 10.3389/fphar.2024.1369178
105. Dimitrova M., Petrov M., **Petrova G.**, Mitkova Z. Economic consequences of the implementation of primary DNA-HPV genotype testing in Bulgaria, *Biotechnology & Biotechnological Equipment*, 2024; 38:1, 2358134, DOI:10.1080/13102818.2024.2358134